View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Oct. 31, 2015	Jan. 07, 2016	Apr. 30, 2015
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-K
Document Period End Date	Oct. 31, 2015
Amendment Flag	false
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Current Reporting Status	Yes
Current Fiscal Year End Date	--10-31
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 445,644,000
Entity Common Stock, Shares Outstanding		33,769,136
Trading Symbol	ADXS
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2015

Balance Sheets - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Current Assets:
Cash and Cash Equivalents	$ 66,561,683	$ 17,606,860
Investments - Held-to-Maturity	45,594,495
Interest Receivable	145,299
Prepaid Expenses	338,841	182,978
Income Tax Receivable	1,609,349	1,731,317
Deferred Expenses - Current	749,790	964,724
Other Current Assets	15,116	8,182
Total Current Assets	115,014,573	20,494,061
Property and Equipment (net of accumulated depreciation)	1,087,244	77,369
Intangible Assets (net of accumulated amortization)	3,355,033	2,767,945
Other Assets	148,843	38,438
TOTAL ASSETS	119,605,693	23,377,813
Current Liabilities:
Accounts Payable	696,117	1,411,058
Accrued Expenses	3,191,941	1,241,796
Short-term Convertible Notes and Fair Value of Embedded Derivative	29,549	62,882
Total Current Liabilities	3,917,607	2,715,736
Common Stock Warrant Liability	89,211	32,091
Total Liabilities	4,006,818	2,747,827
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2015 and 2014. Liquidation preference of $0 at October 31, 2015 and 2014.
Common Stock - $0.001 par value; 45,000,000 shares authorized, 33,591,882 shares issued and 33,574,963 shares outstanding at October 31, 2015 and 19,630,139 shares issued and outstanding at October 31, 2014.	33,592	19,630
Additional Paid-In Capital	249,807,303	107,601,493
Treasury Stock, at cost, 16,919 shares at October 31, 2015 and 0 shares October 31, 2014	(187,761)
Accumulated Deficit	(134,054,259)	(86,991,137)
Total Shareholders' Equity	115,598,875	20,629,986
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 119,605,693	$ 23,377,813

Balance Sheets (Parenthetical) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	33,591,882	19,630,139
Common stock, shares outstanding	33,574,963	19,630,139
Treasury Stock, shares	16,919	0

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Income Statement [Abstract]
Revenue		$ 1,000,000
Research and Development Expenses	24,220,610	8,687,168
General and Administrative Expenses	24,450,047	11,851,410
Total Operating Expenses	48,670,657	20,538,578
Loss from Operations	(48,670,657)	(19,538,578)
Other Income (Expense):
Interest Income	114,219	36,305
Net Changes in Fair Value of Derivative Liabilities	(48,950)	619,089
Other Income (Expense), Net	(35,079)	990
Net Loss Before Income Tax Benefit	(48,640,467)	(18,882,194)
Income Tax Benefit	1,609,349	2,356,880
Net Loss	$ (47,031,118)	$ (16,525,314)
Net Loss per Common Share, Basic and Diluted	$ (1.68)	$ (0.97)
Weighted Average Number of Common Shares Outstanding, Basic and Diluted	28,026,197	17,106,577

Statements of Shareholders' Equity - USD ($)

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Treasury Stock [Member]

Accumulated Deficit [Member]

Total

Balance at Oct. 31, 2013

$ 13,720

$ 88,454,245

$ (70,465,823)

$ 18,002,142

Balance, shares at Oct. 31, 2013

13,719,861

Stock compensation to employees, directors and consultants

$ 502

3,839,202

$ 3,839,202

Stock compensation to employees, directors and consultants, shares

501,651

40,320

Tax withholdings paid related to net share settlement of equity awards

(959,425)

$ (959,425)

Common Stock issued upon exercise of options, shares

Common Stock issued upon exercise of warrants

250

$ 250

Common Stock issued upon exercise of warrants, shares

Common Stock issued to consultants

$ 247

1,551,186

1,551,433

Common Stock issued to consultants, shares

247,218

Conversion of notes payable into common stock

Issuance of shares to employees under ESPP Plan

$ 2

6,249

6,251

Issuance of shares to employees under ESPP Plan, shares

2,110

Issuance of shares to investors under stock purchase agreements

$ 467

2,033,670

2,034,137

Issuance of shares to investors under stock purchase agreements, shares

467,249

Advaxis Public Offering

$ 4,692

12,676,116

12,680,808

Advaxis Public Offering, shares

4,692,000

Net Loss

(16,525,314)

Balance at Oct. 31, 2014

$ 19,630

107,601,493

(86,991,137)

20,629,986

Balance, shares at Oct. 31, 2014

19,630,139

Stock compensation to employees, directors and consultants

$ 790

16,667,800

$ 16,667,800

Stock compensation to employees, directors and consultants, shares

789,438

19,145

Tax withholdings paid related to net share settlement of equity awards

(1,375,979)

$ (1,375,979)

Treasury stock purchased to pay employee withholdings on equity awards

$ (1,388,086)

(1,388,086)

Treasury stock purchased to pay employee withholdings on equity awards, shares

(114,445)

Treasury shares sold to pay for employee tax withhholdings on equity awards

16,273

$ 1,200,325

(32,004)

1,184,594

Treasury shares sold to pay for employee tax withhholdings on equity awards, shares

97,526

Common Stock issued upon exercise of options

$ 65

58,335

$ 58,400

Common Stock issued upon exercise of options, shares

65,167

137,667

^[1]

Common Stock issued upon exercise of warrants

$ 691

2,341,758

$ 2,342,449

Common Stock issued upon exercise of warrants, shares

691,268

Common Stock issued to consultants

$ 379

4,707,061

4,707,440

Common Stock issued to consultants, shares

378,538

Conversion of notes payable into common stock

$ 4

39,928

39,932

Conversion of notes payable into common stock, shares

4,104

Issuance of shares to employees under ESPP Plan

$ 7

28,784

28,791

Issuance of shares to employees under ESPP Plan, shares

7,063

Advaxis registered direct offerings

$ 8,806

63,046,722

63,055,528

Advaxis registered direct offerings, shares

8,806,165

Advaxis Public Offering

$ 3,220

56,675,128

56,678,348

Advaxis Public Offering, shares

3,220,000

Net Loss

(47,031,118)

Balance at Oct. 31, 2015

$ 33,592

$ 249,807,303

$ (187,761)

$ (134,054,259)

$ 115,598,875

Balance, shares at Oct. 31, 2015

33,591,882

(16,919)

[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Statement of Cash Flows - USD ($)	12 Months Ended
Statement of Cash Flows - USD ($)	Oct. 31, 2015	Oct. 31, 2014
OPERATING ACTIVITIES
Net Loss	$ (47,031,118)	$ (16,525,314)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	21,431,030	5,365,610
Non-cash interest expense		51
Loss (Gain) on change in value of warrants and embedded derivative	48,950	(619,089)
Warrant expense	8,170	4,446
(Gain) on disposal of property and equipment	(10,000)
Loss on write-off of intangible assets	28,480
Settlement expense		34,125
Employee Stock Purchase Plan	28,791	6,251
Depreciation expense	59,033	27,611
Amortization expense of intangibles	206,357	175,686
Amortization of premium on held-to-maturity investments	60,608
Debt conversion expense	6,599
(Gain) on note retirement		(6,243)
Change in operating assets and liabilities:
Interest receivable	(145,299)
Prepaid expenses	(155,863)	(151,723)
Taxes receivable	121,968	(1,731,317)
Other current assets	8,066
Deferred expenses	214,934	(617,676)
Security deposit	(110,405)
Accounts payable and accrued expenses	1,094,155	(1,948,987)
Interest payable		(98,192)
Net cash used in operating activities	(24,135,544)	(16,084,761)
INVESTING ACTIVITIES
Investments in held to maturity investments	(45,655,103)
Purchase of property and equipment	(972,859)	(24,595)
Cost of intangible assets	(821,925)	(415,080)
Net cash used in Investing Activities	(47,449,887)	(439,675)
FINANCING ACTIVITIES
Repayment of Officer Loan		(64,926)
Proceeds from exercise of options	58,400
Proceeds from the exercise of warrants	2,342,449	250
Net proceeds of issuance of Common Stock	119,733,876	14,580,808
Tax withholdings paid related to net share settlement of equity awards	(1,375,979)	(936,898)
Treasury stock purchased to pay employee withholdings on equity awards	(1,388,086)
Treasury shares sold to pay for employee tax withholdings on equity awards	1,169,594
Net cash provided by Financing Activities	120,540,254	13,579,234
Net increase (decrease) in Cash and Cash Equivalents	48,954,823	(2,945,202)
Cash and Cash Equivalents at beginning of year	17,606,860	20,552,062
Cash and Cash Equivalents at end of year	66,561,683	17,606,860
Supplemental Disclosures of Cash Flow Information
Cash paid for Interest		103,445
Cash paid for Taxes
Supplemental Schedule of Noncash Investing and Financing Activities
Accounts Payable and Accrued Expenses settled with Common Stock		103,012
Conversion of notes payable into Common Stock	39,932
Sale of treasury shares pending settlement	$ 15,000

Nature of Operations and Basis of Presentation

12 Months Ended

Oct. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Basis of Presentation

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm” or “Listeria”) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Axalimogene filolisbac (ADXS-HPV) is our lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus (“HPV”) associated cancers. The Company completed a randomized Phase 2 study in 110 patients with recurrent cervical cancer that was shown to have a manageable safety profile, apparent improved survival and objective tumor responses. In addition, the Gynecologic Oncology Group (“GOG”), now part of NRG Oncology, is conducting a cooperative group sponsored Phase 2 open-label clinical study of axalimogene filolisbac in patients with persistent or recurrent cervical cancer with documented disease progression. The study, known as GOG-0265, has successfully completed its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient recruitment. The Company plans to advance this immunotherapy into a registrational clinical trial for the treatment of women with high-risk locally advanced cervical cancer.

Axalimogene filolisbac has received United States Food and Drug Administration (“FDA”) orphan drug designation for three HPV-associated cancers: cervical, head and neck, and anal cancer, and has received European Medicines Agency (“EMA”) orphan drug designation for anal cancer. It is being evaluated in Company-sponsored trials executed under an Investigational New Drug (“IND”) which include the following: i) a Phase 1/2 clinical trial alone and in combination with MedImmune, LLC’s (“MedImmune”) investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in patients with previously treated metastatic cervical cancer and HPV-associated head and neck cancer; ii) a Phase 2 multi-center, open-label study alone and in combination with Incyte Corporation’s (“Incyte”) investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360) in patients with Stage I-IIa cervical cancer; iii) a Phase 1/2 study evaluating higher doses and repeat cycles of axalimogene filolisbac in patients with recurrent cervical cancer; iv) a single arm Phase 2 monotherapy study in patients with metastatic anal cancer; and v) a Phase 2 study in collaboration with and funded by Global BioPharma Inc. (“GBP”), under a development and commercialization license agreement applicable to Asia, of axalimogene filolisbac in HPV-associated non-small cell lung cancer. In addition to the Company-sponsored trials, axalimogene filolisbac is also being evaluated in three ongoing investigator-initiated clinical trials as follows: locally advanced cervical cancer (GOG-0265), head and neck cancer (Mount Sinai), and anal cancer (Brown University).

ADXS-PSA is the Company’s Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (“PSA”) associated with prostate cancer. This Phase 1/2 clinical trial is alone and in combination with KEYTRUDA® (pembrolizumab), Merck & Co.’s (“Merck”) humanized monoclonal antibody against PD-1, in patients with previously treated metastatic castration-resistant prostate cancer.

ADXS-HER2 is the Company’s Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (“HER2”) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers. This Phase 1b clinical trial is in patients with metastatic HER2 expressing solid tumors. We received orphan drug designation from both the FDA and EMA for ADXS-HER2 in osteosarcoma. Clinical research with ADXS-HER2 in canine osteosarcoma is being developed by our pet therapeutic partner, Aratana Therapeutics Inc. (“Aratana”), who holds exclusive rights to develop and commercialize ADXS-HER2 and three other Lm-LLO immunotherapies for pet health applications. Aratana has announced that a product license application for use of ADXS-HER2 in the treatment of canine osteosarcoma has been filed with the United States Department of Agriculture (“USDA”). Aratana received communication from the USDA in March 2015 stating that the previously submitted efficacy data for product licensure for AT-014 (ADXS-HER2), the cancer immunotherapy for canine osteosarcoma, was accepted and that it provides a reasonable expectation of efficacy that supports conditional licensure. While additional steps need to be completed, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2016.

In October of 2015, the Company received notification from the FDA that the INDs for axalimogene filolisbac were put on clinical hold in response to its submission of a safety report to the FDA. The clinical hold also included the INDs for ADXS-PSA and ADXS-HER2. Following discussions with the FDA and in accordance with their recommendations, the Company agreed to implement certain risk mitigation measures, including revised study protocol inclusion / exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures. In December 2015, the FDA notified the Company that the hold has been lifted with respect to its INDs.

The Company has focused its development efforts on understanding its platform technology and establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, with clinical trials currently targeting HPV-associated cancer (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2-expressing cancers. Although no immunotherapies have been commercialized to date, the Company continues to invest in research and development to advance the technology and make it available to patients with many different types of cancer. Pipeline development and the further exploration of the technology for advancement entails risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting and expanding its clinical development program. In addition to its existing single antigen vectors that target one tumor associated antigen, the Company is actively engaged in the development of new constructs that will address multiple targets that are common to tumor types, as well as mutation-associated neo-epitopes that are specific to an individual patient’s tumor. Lastly, the Company is developing certain internal capabilities to produce supplies for its neoepitope and its other programs.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock (“Common Stock”). The transaction closed on December 22, 2014, and the Company received net proceeds of approximately $15.8 million from the offering. In addition, on February 18, 2015, the Company priced an additional registered direct offering of 3,068,095 shares of its Common Stock. The transaction closed on February 19, 2015, and the Company received net proceeds of approximately $22.3 million from the offering. The shares in each offering were sold under a Registration Statement (No. 333-194009) on Form S-3, filed by the Company with the United States Securities and Exchange Commission (“SEC”). On May 5, 2015, the Company closed on an underwritten public offering of 2,800,000 shares of Common Stock at a public offering price of $19.00 per share. On May 20, 2015, the Company closed the Underwriters’ overallotment option to purchase 420,000 shares of its Common Stock at a public offering price of $19.00 per share. The net proceeds from the May 2015 public offerings were approximately $56.7 million. On August 25, 2015, the Company priced a registered direct offering of 1,797,269 of its Common Stock at a price of $13.91 per share. The transaction closed on August 28, 2015 and the Company received net proceeds of approximately $25 million. The sale of the shares in these offerings were registered pursuant to a Registration Statement (No. 333- 203497) on Form S-3, filed by the Company with the SEC.

The Company believes its current cash position is sufficient to fund its business plan approximately through calendar year end 2017. The estimate is based on assumptions that may prove to be wrong, and the Company could use available capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development and commercialization of its product candidates, the Company is unable to estimate the amount of increased capital outlays and operating expenses associated with completing the development of its current product candidates.

The Company recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan.

Summary of Significant Accounting Policies

12 Months Ended

Oct. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates

The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of investments, the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Revenue Recognition

The Company derived all of its revenue in 2014 from patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability.

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company’s performance obligations under the collaboration agreement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s consolidated statements of operations.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of October 31, 2015 and October 31, 2014, the Company had approximately $62.8 million and $17.5 million in cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $63.9 million is subject to credit risk at October 31, 2015. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Investments

Investment securities at October 31, 2015 consist of certificates of deposit, domestic governmental agency loans, and U.S. treasury notes. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold the security until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method.

A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in Other Income (Expense), net. The Company did not recognize any impairment charges during the year ended October 31, 2015. Interest income is recognized when earned.

Deferred Expenses

Deferred Expenses consist of advanced payments made on research and development projects. Amortization is provided for on a straight-line basis over the periods of the underlying research and development contracts ranging from six months to five years and is charged to Research and Development Expense in the Statement of Operations.

Property and Equipment

Property and equipment consists of computer equipment, laboratory equipment, furniture and fixtures and leasehold improvements and is stated at cost. Depreciation and amortization is provided for on the straight-line basis over the estimated useful lives of the respective asset ranging from three to 10 years. Leasehold Improvements are amortized over the lesser of the asset’s economic life or the lease term. Expenditures for maintenance and repairs that do not materially extend the useful lives of the respective assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations.

Intangible Assets

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line basis over their remaining useful lives which are estimated to be 20 years from the effective dates of the University of Pennsylvania (Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn and its patent attorneys.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before Advaxis or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of October 31,
	2015		2014
Warrants		3,241,466		4,158,092
Stock Options		1,981,939		467,968
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,224,981		4,629,414

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.

Treasury Stock

The Company accounts for repurchases of common stock and shares withheld in lieu of taxes when restricted stock vests using the cost method with common stock in treasury classified in the balance sheet as a reduction in stockholders’ equity.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Amendments in this ASU create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is the final version of Proposed ASU 2011-230—Revenue Recognition (Topic 605) and Proposed ASU 2011–250—Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this ASU are effective for the Company for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, Disclosures of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company does not expect that this guidance will have a material impact on its financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

Investments

12 Months Ended

Oct. 31, 2015

Investments

Investments

3. INVESTMENTS

The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2015:

	October 31, 2015
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	12,628,880	$	-	$	-	$	12,628,880
Domestic Governmental Agency Loans		27,951,633		5,827		5,979		27,951,481
U.S Treasury Notes		5,013,982		700		262		5,014,420
Total short-term investment securities	$	45,594,495	$	6,527	$	6,241	$	45,594,781

All of the Company’s investments mature within the next 12 months.

Property and Equipment

12 Months Ended

Oct. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

4. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	October 31,
	2015			2014
Leasehold Improvements	$	237,209		$	-
Laboratory Equipment		532,249			250,456
Furniture and Fixtures		331,500			72,554
Computer Equipment		48,745			10,717
Construction in Progress		80,538			-
Total Property and Equipment		1,230,241			333,727
Accumulated Depreciation and Amortization		(142,997	)		(256,358	)
Net Property and Equipment	$	1,087,244		$	77,369

Depreciation expense for the years ended October 31, 2015 and 2014 was $59,033 and $27,611, respectively.

Intangible Assets

12 Months Ended

Oct. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

5. INTANGIBLE ASSETS

Under the University of Pennsylvania (“Penn”) license agreements, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from the Company’s patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31,
	2015			2014
License	$	651,992		$	651,992
Patents		3,898,493			3,111,624
Total intangibles		4,550,485			3,763,616
Accumulated Amortization		(1,195,452	)		(995,671	)
Net Intangible Assets	$	3,355,033		$	2,767,945

The expirations of the existing patents range from 2015 to 2030 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $28,480 and $- were abandoned and were charged to Other Income (Expense), Net in the statement of operations for the years ended October 31, 2015 and 2014, respectively. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $206,357 and $175,686 for the years ended October 31, 2015 and 2014.

Estimated amortization expense for the next five years is as follows:

Year ending October 31,
2016	$	221,000
2017	$	221,000
2018	$	221,000
2019	$	221,000
2020	$	221,000

Accrued Expenses

12 Months Ended

Oct. 31, 2015

Payables and Accruals [Abstract]

Accrued Expenses

6. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	October 31,
	2015		2014
Salaries and other compensation	$	1,698,371	$	890,069
Vendors		1,000,579		121,200
Professional Fees		272,058		208,000
Withholding taxes payable		220,933		22,527
Total Accrued Expenses	$	3,191,941	$	1,241,796

Convertible Notes and Fair Value of Embedded Derivative

12 Months Ended

Oct. 31, 2015

Debt Disclosure [Abstract]

Convertible Notes and Fair Value of Embedded Derivative

7. CONVERTIBLE NOTES AND FAIR VALUE OF EMBEDDED DERIVATIVE

Junior Subordinated Convertible Promissory Notes

The Company refers to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes.”

The Bridge Notes are convertible into shares of the Company’s Common Stock at a fixed exercise price. As of October 31, 2015 and 2014, the Company had approximately $30,000 and $63,000 in principal outstanding on its junior subordinated convertible promissory notes that are currently overdue and are recorded as current liabilities on the Company’s balance sheet at October 31, 2015 and 2014, respectively.

During February 2015, the Company induced certain noteholders to convert their convertible promissory notes into common shares by offering conversion prices at a $1.61 discount from the market price of the common stock. In total, $33,333 of promissory notes were converted into 4,104 shares of common stock. In connection with the note conversions, the Company recorded a debt conversion expense of $6,599 in the accompanying statement of operations

Embedded Derivative Liability

The Company has convertible features (known as “Embedded Derivatives”) in its outstanding convertible promissory note. The Embedded Derivatives are recorded as liabilities at issuance. These Embedded Derivatives are valued using the BSM and are subject to revaluation at each reporting date. Any change in fair value between reporting periods will be reported on the statement of operations.

The fair value of the Warrants and Embedded Derivatives are estimated using an adjusted BSM model. The Company computes multiple valuations, each quarter, using the BSM model for each derivative instrument to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the derivative at the reporting date.

At October 31, 2015 and October 31, 2014, the fair value of the Embedded Derivative Liability was $0 as the related notes were paid off, converted or reached maturity.

Common Stock Purchase Warrants and Warrant Liability

12 Months Ended

Oct. 31, 2015

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

8. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of October 31, 2015, there were outstanding warrants to purchase 3,241,466 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $18.75 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	18.75		7,902	January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	10.63		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.63-18.75		3,172	November 2015 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	2.76-5.52		122,661	December 2015 – March 2024	Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75		1,778	August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,043,477	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	3.75-5.00		28,375	October 2018 – March 2019	Representative – Advaxis Public Offering
		Grand Total		3,241,466

As of October 31, 2014, there were outstanding warrants to purchase 4,158,092 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		10,059	October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 – January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	7.77-21.25		112,460	December 2014 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		7,855	January 2015 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	4.90		30,154	September 2015	Consultant
Common Stock Purchase Warrant	$	2.76-5.52		277,055	December 2015 – March 2024	Stock Purchase Agreement
Common Stock Purchase Warrant	$	5.625-18.75		13,095	October 2015 – August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,306,200	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	3.75-5.00		320,775	October 2018 – March 2019	Representative – Advaxis Public Offering
		Grand Total		4,158,092

A summary of changes in warrants for the years ended October 31, 2015 and 2014 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and Exercisable Warrants at October 31, 2013		4,265,262		$	6.71		4.22	$	22,208
Issued		412,693			4.97
Exercised		(50	)		5.00
Expired		(519,813	)		15.01
Outstanding and Exercisable Warrants at October 31, 2014		4,158,092		$	5.43		3.94	$	9,518
Issued		2,361			7.20
Exercised *		(769,349	)		5.12
Expired		(149,638	)		14.61
Outstanding and Exercisable Warrants at October 31, 2015		3,241,466		$	5.07		2.90	$	19,588,099

* Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock.

At October 31, 2015, the Company had approximately 3.22 million of its total 3.24 million outstanding warrants classified as equity (equity warrants). At October 31, 2014, the Company had approximately 4.04 million of its total 4.16 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet. The Company’s equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

Warrant Liability

At October 31, 2015, the Company had approximately 18,000 of its total 3.24 million outstanding warrants classified as liability warrants (Common Stock warrant liability). At October 31, 2014, the Company had approximately 123,000 of its total 4.16 million outstanding warrants classified as liability warrants (Common Stock warrant liability). All of these liability warrants at October 31, 2015 and October 31, 2014 were outstanding. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At October 31, 2015, none of the 18,000 liability warrants are subject to weighted-average anti-dilution provisions. At October 31, 2014, approximately 60,000 of the 123,000 liability warrants are subject to weighted-average anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At October 31, 2015 and October 31, 2014, the fair value of the warrant liability was $89,211 and $32,091, respectively. For the twelve months ended October 31, 2015 and 2014, the Company reported a loss of $48,950 and income of $619,089, respectively, due to changes in the fair value of the warrant liability.

In fair valuing the warrant liability, at October 31, 2015 and October 31, 2014, the Company used the following inputs in its BSM:

		10/31/2015			10/31/2014

Exercise Price	$	10.63-18.75		$	2.76-21.25
Stock Price	$	11.09		$	3.18
Expected Term		1.52-1.76 years			0.01-2.76 years
Volatility %		93.87%-95.00	%		55.41% -129.38	%
Risk Free Rate		.075	%		.01%-1.62	%

Exercise of Warrants

During the twelve months ended October 31, 2015, accredited investors exercised 769,349 warrants at a weighted average exercise price of $5.12, resulting in net proceeds to the Company of $2,342,449.

During the twelve months ended October 31, 2014, an accredited investor exercised 50 warrants at an exercise price of $5.00, resulting in net proceeds to the Company of $250.

Expiration of Warrants

During the twelve months ended October 31, 2015, the Company had 62,430 warrants with anti-dilution provisions, and 87,208 warrants, with no such anti-dilution provisions, expired unexercised.

During the twelve months ended October 31, 2014, the Company had 179,666 warrants with anti-dilution provisions, and 340,147 warrants, with no such anti-dilution provisions, expired unexercised.

Warrants with anti-dilution provisions

Some of the Company’s warrants contained anti-dilution provisions originally set at an exercise price of $25.00 with a term of five years. As of October 31, 2015, all of these warrants had expired. As of October 31, 2014, these warrants had an exercise price of approximately $7.71. If the Company had issued any Common Stock, except for exempt issuances as defined in the warrant agreement, for consideration less than the exercise price, then the exercise price and the amount of warrant shares available would have been adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant agreement. For the twelve months ended October 31, 2015, this anti-dilution provision required the Company to issue approximately 2,400 additional warrant shares, and the exercise price to be lowered to $7.20.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computed multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $7.20 and $6.00, weighting the possibility of warrants being exercised at $7.20 between 40% and 50% and warrants being exercised at $6.00 between 50% and 60%.

Share Based Compensation

12 Months Ended

Oct. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation

9. SHARE BASED COMPENSATION

Amendments

On March 30, 2015, the Board of Directors adopted, subject to stockholder approval at the Annual Meeting, the Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”). The 2015 Plan became effective on May 27, 2015 when it was approved by the Company’s stockholders at the 2015 Annual Meeting. The 2015 Plan serves as the successor to the Advaxis, Inc. 2011 Omnibus Incentive Plan (the “Prior Plan”). Effective May 27, 2015, all future equity awards were made from the 2015 Plan, and no additional awards will be granted under the Prior Plan. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of Common Stock that may be issued under the 2015 Plan is 3,600,000 shares, plus a number of additional shares (not to exceed 650,000) underlying awards outstanding as of the effective date of the 2015 Plan under the Prior Plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason. As of October 31, 2015, there were 2,134,468 shares available for issuance under the 2015 Plan.

At the Annual Meeting of Stockholders of the Company held on July 9, 2014, the stockholders ratified and approved an amendment to the Company’s 2011 Omnibus Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 520,000 shares to 2,120,000 shares. Furthermore, the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares of common stock to 45,000,000 shares of common stock.

Employment Agreements

Management voluntarily purchases restricted stock directly from the Company at market price. The respective stock purchases occur on the last trading day of each month. This voluntary election is outlined in each of Daniel J. O’Connor, Chief Executive Officer and President, David J. Mauro, Executive Vice President, Chief Medical Officer, Gregory T. Mayes, Executive Vice President, Chief Operating Officer and Secretary, Robert G. Petit, Executive Vice President, Chief Scientific Officer and Sara M. Bonstein, Senior Vice President, Chief Financial Officer, (each an “Executive”), employment agreements. The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Year Ended October 31, 2015
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	89,064	$	88,840		8,482	$	76,451		7,556
David J. Mauro	$	16,531	$	16,491		1,591	$	12,729		1,252
Gregory T. Mayes	$	23,477	$	23,312		2,180	$	18,740		1,781
Robert G. Petit	$	25,225	$	25,220		2,443	$	19,000		1,886
Sara M. Bonstein	$	19,734	$	19,597		1,837	$	15,662		1,473

For the twelve months ended October 31, 2015, the Company recorded stock compensation expense of $206,192 for the portion of management salaries paid in stock, representing 19,145 shares of its Common Stock (16,090 shares on a net basis after employee payroll taxes).

For the twelve months ended October 31, 2014, the Company recorded stock compensation expense of $128,271 for the portion of management salaries paid in stock, representing 40,320 shares of its Common Stock (31,026 shares on a net basis after employee payroll taxes).

From 2013 to present, in addition to the purchases of Common Stock set forth in the above table, Mr. O’Connor has also purchased an additional 146,616 shares of Common Stock out of his personal funds at the then market price for an aggregate consideration of $588,294. These purchases consisted of the conversion of amounts due to Mr. O’Connor under a promissory note given by Mr. O’Connor to the Company in 2012 of $66,500 for 21,091 shares, 2013 base salary which he elected to receive in Common Stock of a $186,555 for 34,752 shares (21,489 on a net basis after employee payroll taxes), 2013 and 2014 cash bonuses voluntarily requested to receive in equity of $214,359 for 62,064 shares (57,990 on a net basis after employee payroll taxes), fiscal 2014 voluntary request to purchase stock directly from the Company at market price purchases of $68,750 for 15,950 shares, and purchases of the Company’s Common Stock in the October 2013 and March 2014 public offerings of 13,500 shares for $54,000 and 3,333 shares for $10,000.

For the twelve months ended October 31, 2015, executive officers received a portion of their year-end performance bonus (with a total fair value of approximately $418,000) in the aggregate amount of 125,411 shares of the Company’s Common Stock (98,603 on a net basis after employee payroll taxes).

For the twelve months ended October 31, 2014, executive officers received a portion of their year-end performance bonus (with a total fair value of approximately $129,000) in the aggregate amount of 31,845 shares of the Company’s Common Stock (21,389 on a net basis after employee payroll taxes).

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the twelve months ended October 31, 2015 and 2014 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2013:		112,500		$	3.57
Granted		1,268,580			3.88
Vested		(547,030	)		3.91
Cancelled		(42,171	)		4.14
Balance at October 31, 2014:		791,879		$	3.81
Granted		864,192			15.14
Vested		(583,403	)		7.58
Cancelled		(3,333	)		11.76
Balance at October 31, 2015		1,069,335		$	10.89

The fair value as of the respective vesting dates of RSUs was approximately $7,771,000 and $1,944,000 for the twelve months ended October 31, 2015 and 2014, respectively.

As of October 31, 2015, there was approximately $10,053,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.26 years.

As of October 31, 2015, the aggregate intrinsic value of non-vested RSUs was approximately $217,908.

Employee Stock Awards

During the twelve months ended October 31, 2015, 487,591 shares of Common Stock (406,691 shares on a net basis after employee taxes) were issued to executives and employees related to incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $5,226,302.

Furthermore, non-executive employees were entitled to receive a performance-based year-end cash bonus. Several non-executive employees requested to be paid all or a portion of their cash bonus in the Company’s Common Stock instead of cash. During the twelve months ended October 31, 2015, the total fair value of these equity purchases were $67,671, or 20,322 shares of the Company’s Common Stock (14,300 on a net basis after employee payroll taxes).

During the twelve months ended October 31, 2014, 489,287 shares of Common Stock (280,848 shares on a net basis after employee taxes) were issued to executives and employees related to incentive retention awards, employment inducements and employee excellence awards. Total stock compensation expense associated with these awards was $1,836,143.

Director Stock Awards

During the twelve months ended October 31, 2015, 267,186 shares of Common Stock (253,754 shares on a net basis after taxes) were issued to the Directors for compensation related to board and committee membership. Total stock compensation expense to the Directors was $1,223,118.

During the twelve months ended October 31, 2014, 146,899 shares of Common Stock were issued to the Directors for compensation related to board and committee membership. Total stock compensation expense to the Directors was $614,750.

Stock Options

A summary of changes in the stock option plan for the twelve months ended October 31, 2015 and 2014 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2013		467,923		$	15.86		7.28	$	-
Granted		36,000			4.02		9.16
Cancelled or Expired		(35,955	)		8.57		-
Outstanding as of October 31, 2014		467,968		$	15.51		6.34	$	-
Granted		1,668,995			13.41		9.42
Exercised *		(137,667	)		12.29
Cancelled or Expired		(17,357	)		36.24
Outstanding as of October 31, 2015		1,981,939		$	13.78		8.72	$	285,330
Vested and Exercisable at October 31, 2015		711,742		$	14.15		7.46	$	270,556

* Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

The following table summarizes information about the outstanding and exercisable options at October 31, 2015.

	Options Outstanding								Options Exercisable
			Weighted		Weighted						Weighted
			Average		Average						Average
Exercise	Number		Remaining		Exercise		Intrinsic		Number		Exercise		Intrinsic
Price Range	Outstanding		Contractual		Price		Value		Exercisable		Price		Value

$3.00 - $9.99		119,720		7.40	$	8.71	$	285,330		117,719	$	8.79	$	270,556
$10.00 - $14.99		1,621,605		9.24	$	13.41	$	-		403,409	$	13.31	$	-
$15.01 - $19.99		224,669		6.33	$	18.06	$	-		174,669	$	18.30	$	-
$20.00 - $36.00		15,945		0.45	$	29.27	$	-		15,945	$	29.27	$	-

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2015 and 2014 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s Common Stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options’ expected lives. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

In determining the fair value of the stock options granted during the twelve months ended October 31, 2015 and 2014, the Company used the following inputs in its BSM:

	Year Ended
	October 31, 2015			October 31, 2014

Expected Term		5-10 years			5 years
Expected Volatility		109.26%-154.54	%		151.38%-171.12	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.41%-2.27	%		1.39%-1.72	%

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for twelve months ended October 31, 2015 and 2014 was approximately $9,521,000 and $920,000, respectively.

During the twelve months ended October 31, 2015, 1,668,995 options were granted with a total grant date fair value of approximately $29,014,000. During the twelve months ended October 31, 2014, 36,000 options were granted with a total grant date fair value of approximately $145,000.

During the twelve months ended October 31, 2015, options to purchase 137,667 shares of common stock were exercised, which resulted in cash proceeds of $58,400.

As of October 31, 2015, there was approximately $19,718,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.35 years.

As of October 31, 2015, the aggregate intrinsic value of vested and exercisable options was approximately $271,000.

Shares Issued to consultants

During the twelve months ended October 31, 2015, 378,538 shares of Common Stock valued at $4,707,440 were issued to consultants for services. The Company recorded a liability on its balance sheet for $55,000 for shares earned pursuant to consulting agreements but not delivered.

During the twelve months ended October 31, 2014, 405,603 shares of Common Stock valued at $1,551,591 were issued to consultants for services. The common stock share values were based on the dates the shares vested.

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for years ended October 31, 2015 and 2014, respectively:

	Year Ended October 31,
	2015		2014
Research and development	$	6,293,791	$	1,250,747
General and administrative		15,137,239		4,114,863
Total	$	21,431,030	$	5,365,610

2011 Employee Stock Purchase Plan

The Company’s Board of Directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which the Company’s refers to as the ESPP, on August 22, 2011, and the Company’s shareholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase Common Stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 40,000 shares of the Company’s Common Stock are reserved for issuance under the ESPP.

During the twelve months ended October 31, 2015, $28,791 was withheld from employees, on an after-tax basis, in order to purchase an aggregate of 7,063 shares of Company’s Common Stock. During the twelve months ended October 31, 2014, $6,251 was withheld from employees, on an after-tax basis, in order to purchase 2,110 shares of the Company’s Common Stock. As of October 31, 2015, 22,827 shares of Company’s Common Stock remain available for issuance under the ESPP.

Commitments and Contingencies

12 Months Ended

Oct. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES:

Legal Proceedings

Iliad Research and Trading

On March 24, 2014, Iliad Research and Trading, L.P. (“Iliad”) filed a Complaint against the Company in the Third Judicial District Court of Salt Lake County, Utah. On June 30, 2014, after Iliad had filed an Amended Complaint, the Company removed the action to the United States District Court for the District of Utah. On August 1, 2014, Iliad filed a Second Amended Complaint (the “SAC”). Iliad alleged that the Company granted a participation right to Tonaquint, Inc. (“Tonaquint”) in a securities purchase agreement between Tonaquint and the Company (the “Purchase Agreement”), pursuant to which Tonaquint was entitled to participate in transactions that the Company structured in accordance with Section 3(a)(10) of the Securities Act of 1933, as amended. Iliad further alleged that the Company’s settlement with Ironridge Global IV, Ltd. (“Ironridge”), pursuant to which the Company issued certain shares of its Common Stock to Ironridge in reliance on the Section 3(a)(10) exemption, occurred without adequate notice for Tonaquint to exercise its participation right. In addition, Iliad alleged that it acquired all of Tonaquint’s rights under the Purchase Agreement in April 2013. The SAC purports to assert claims for breach of contract (express and implied), fraud (federal securities, state securities and common law) and conversion.

On November 24, 2014, in response to the Company’s motion to dismiss, the Court dismissed the conversion claim but denied the remainder of the motion. On December 8, 2014, Advaxis filed its answer to the SAC and a counterclaim (the “Counterclaim”), alleging that Iliad – by purporting to have surreptitiously preserved its claim for breach of Tonaquint’s alleged right to participate in the Ironridge transaction – had fraudulently induced Advaxis to enter into the parties’ post-assignment Exchange and Settlement Agreement and, in the alternative, had breached the covenant of good faith and fair dealing implied therein. On January 23, 2015, Iliad filed its Reply to Counterclaim. On May 4, 2015, in response to Iliad’s motion for partial summary judgment concerning liability on the express contract claim and Advaxis’ Rule 56(d) motion to deny that motion and allow discovery, the Court found that Advaxis had materially breached the Purchase Agreement.

On September 10, 2015, the parties entered into a definitive confidential settlement agreement and the case was dismissed.

KCM

On August 21, 2015, Knoll Capital Management L.P. (“KCM”) filed a complaint against the Company in the Delaware Court of Chancery. The complaint alleges the existence of an oral agreement for the purchase by Knoll from the Company of 1,666,666.67 shares of Company stock at a price of $3.00 per share. KCM alleges that the Company breached this alleged agreement and seeks specific performance or, alternatively, money damages for breach of contract. KCM served the Company with the complaint on August 31, 2015, and then served an amended complaint on October 16, 2015. The Company moved to dismiss the amended complaint on October 26, 2015. A hearing on the motion to dismiss is scheduled for January 11, 2016. The Company intends to defend itself vigorously.

Numoda

On June 19, 2009, the Company entered into a master agreement, and on July 8, 2009, entered into a Project Agreement with Numoda Corporation (“Numoda”), to oversee Phase 2 clinical activity with axalimogene filolisbac for the treatment of invasive cervical cancer and cervical intraepithelial neoplasia.

On October 1, 2014, the Company filed a Complaint against Numoda seeking a declaratory judgment that, with its tender to Numoda of a check for $68,884, the Company had fully performed the parties’ Project Agreement and that Numoda was not entitled to interest, costs or attorneys’ fees thereunder or otherwise. On January 23, 2015, the Company filed an Amended Complaint against Numoda seeking an order directing Numoda to specifically perform its obligation to deliver to Advaxis all materials, information and other data generated under the parties’ Project Agreement. On February 20, 2015, Numoda filed an Answer denying liability and asserting a number of affirmative defenses. With Court approval of a stipulation of the parties, the Preliminary Conference was adjourned from May 28, 2015 until October 29, 2015. Before the Preliminary Conference occurred, the Court adjourned it without date. On November 20, 2015, the Company and Numoda reached a confidential agreement in principal, which is subject to more formal documentation, to resolve the action.

Larkin and Bono

On July 27, 2015, a derivative complaint was filed by a purported Company shareholder in the Court of Chancery of the State of Delaware against certain of the Company’s officers and directors styled Timothy Larkin v. O’Connor, et al., Case No. 11338-CB (Del. Ch. July 27, 2015). The action was brought derivatively on behalf of the Company, which is also named as a nominal defendant. On August 20, 2015, a related derivative complaint was filed by a purported Company shareholder in the United States District Court for the District of New Jersey against the same defendants styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015). Both complaints are based on general allegations related to certain stock options granted to the individual defendants and generally allege counts for breaches of fiduciary duty and unjust enrichment. The Bono complaint alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. Both complaints seek damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief. At this early stage of each proceeding, the Company does not express any opinion as to the likely outcome, but the Company intends to defend each action vigorously. On September 30, 2015, Defendants in the Larkin action filed a Motion to Dismiss, which is currently pending. On October 27, 2015, Defendants in the Bono action filed a Motion to Dismiss the Verified Stockholder Derivative Complaint or, in the Alternative, to Stay, which is currently pending.

Clinical Trial Collaboration Agreements

Inctye

On February 10, 2015, the Company entered into a Clinical Trial Collaboration Agreement (the “Incyte Agreement”) with Incyte Corporation (“Incyte”) for the development and analysis of a combination therapy for the treatment of cervical cancer. Under the terms of the Incyte Agreement, the parties will contribute their respective compounds to be dosed in combination during the course of the study, with Incyte acting as the sponsor of the study and taking the lead role in its conduct. The Incyte Agreement is to continue in full force and effect until completion of the final study report or until earlier termination by either party. Costs for the study are to be split between the parties, and Incyte will provide us with an invoice and supporting documents of our share of the costs incurred through the end of each calendar quarter. During the year ended October 31, 2015, the Company incurred approximately $124,100 in expenses pertaining to the Incyte agreement, and such expenses were a component of research and development expenses in the statement of operations.

Merck& Co., Inc.

On August 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties will collaborate on a Phase 1/2 dose-escalation and safety study. The Phase 1 portion of the study will evaluate the safety of our Lm-LLO based immunotherapy for prostate cancer, ADXS31-142 (the “Advaxis Compound”) as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, (the “Merck Compound”) to determine a recommended Phase 2 combination dose. The Phase 2 portion will evaluate the safety and efficacy of the Advaxis Compound in combination with the Merck Compound. Both phases of the study will be in patients with previously treated metastatic castration-resistant prostate cancer. A joint development committee, comprised of equal representatives from both parties, is responsible for coordinating all regulatory and other activities under, and pursuant to, the Merck Agreement.

Each party is responsible for their own internal costs and expenses to support the study, while we will be responsible for all third party costs of conducting the study. Merck will be responsible for manufacturing and supplying the Merck Compound. We will be responsible for manufacturing and supplying the Advaxis Compound. The Company will be the sponsor of the study and hold the IND related to the study.

All data and results generated under the study (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of us. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck.

The Merck Agreement shall continue in full force and effect until completion of all of the obligations of the parties or a permitted termination.

During the years ended October 31 2015 and 2014, the Company incurred approximately $1,723,000 and $72,000, respectively, in expenses pertaining to the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations.

MedImmune/AstraZeneca

On July 21, 2014, the Company entered into a Clinical Trial Collaboration Agreement (the “MedImmune Agreement”) with MedImmune, the global biologics research and development arm of AstraZeneca, pursuant to which the parties intend to initiate a Phase 1/2 clinical study in the United States to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with our investigational Lm-LLO cancer immunotherapy, axalimogene filolisbac , as a combination treatment for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer. A joint steering committee, composed of equal representatives from both parties, is responsible for various matters associated with the collaboration, including protocol approval, as well as reviewing and monitoring the progress of the study.

MedImmune will be responsible for providing MEDI4736 at no cost, as well as costs related to the proprietary assays performed by MedImmune or a third party on behalf of MedImmune. We will be the sponsor of the study and be responsible for the submission of all regulatory filings to support the study, the negotiation and execution of the clinical trial agreements associated with each study site, and the packaging and labelling of the Advaxis and MedImmune product candidates to be used in the study and the costs associated therewith. For a period beginning upon the completion of the study and the receipt by MedImmune of the last final report for the study and ending one hundred twenty (120) days thereafter (unless extended), MedImmune will be granted first right to negotiate in good faith in an attempt to enter into an agreement with us with respect to the development, regulatory approval and commercialization of axalimogene filolisbac and MEDI4736 to be used in combination with each other for the treatment or prevention of cancer. Neither party is obligated to enter into such an agreement. In the event the parties do not enter an agreement and we obtain regulatory approval for axalimogene filolisbac in combination with any PD-1 antibody or PD-L1 antibody, we shall pay MedImmune a royalty obligation and one-time payment.

All intellectual property rights made, conceived or generated through the clinical trials that relate solely to a MedImmune development product shall be owned solely by MedImmune. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to an Advaxis development product shall be owned solely by us. All intellectual property rights made, conceived or generated through the clinical trials that relate to the combination of one or more MedImmune development product and one or more Advaxis development product shall be jointly owned by both parties; provided, however that in the event the parties do not enter into a clinical development and commercialization agreement, we will not exploit, commercialize or license the joint inventions, except for the performance of its obligations under the MedImmune Agreement. MedImmune has the sole right to prosecute and enforce all patents and other intellectual property rights covering all joint inventions and all associated costs will be shared by the parties.

The MedImmune Agreement shall remain in effect until the earlier of (i) permitted termination, (ii) the parties entering into a clinical development and commercialization agreement or expiration of the negotiation period (unless extended), except with respect to rights that survive termination. Either party may terminate the MedImmune Agreement upon thirty (30) days written notice upon material breach of the other party, unless the breach is cured in such period or reasonable actions to cure the breach are initiated and pursued (if the breach is not capable of being cured during the 30-day notice period). In addition, either party may terminate the MedImmune Agreement immediately if the party determines in good faith that the trials may unreasonably affect the safety of trial subjects.

During the years ended October 31 2015 and 2014, the Company incurred approximately $1,888,000 and $50,000, respectively, in expenses pertaining to the MedImmune agreement, and such expenses were a component of research and development expenses in the statement of operations.

Office& Laboratory Lease

The Company’s corporate offices are currently located at 305 College Road East, Princeton, New Jersey 08540. On April 1, 2011, the Company entered into a sublease agreement for such office, and the agreement expired on November 29, 2015.

In May 2015, the Company signed a direct lease for an expansion area, as well as a direct lease for the existing office, lab and vivarium space upon the expiration of the sublease agreement, which is approximately 20,000 square foot of space in total in Princeton, NJ. The lease term is seven years and expires on November 30, 2022. The Company paid a security deposit of $82,426. The lease requires base annual rent of approximately $442,000 with annual increases in increments between 2% and 4% throughout the remainder of the lease. Rent expense will be recognized on a straight line basis over the term of the lease. The lease contains two options to renew for five years each.

Rent expense for the years ended October 31, 2015 and 2014 was $150,000 and $330,000, respectively.

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2016	$	440,208
2017		450,541
2018		468,947
2019		488,153
2020		507,359
Thereafter		1,117,949

The Company plans to continue to rent necessary offices and laboratories to support its business.

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In December 2015, the Company received a net cash amount of $1,609,349 from the sale of its state NOLs and research and development tax credits for the period ended October 31, 2014. In December 2014, the Company received a net cash amount of $1,731,317 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2012 and 2013.

Income Taxes

12 Months Ended

Oct. 31, 2015

Income Taxes

Income Taxes

11. INCOME TAXES:

The income tax provision (benefit) consists of the following:

	October 31, 2015			October 31, 2014
Federal
Current	$	-		$	-
Deferred		(14,513,684	)		(5,777,937	)
State and Local
Current		(1,609,349	)		(2,356,880	)
Deferred		(1,840,276	)		1,008,338
Change in valuation allowance		16,353,960			4,769,599
Income tax provision (benefit)	$	(1,609,349	)	$	(2,356,880	)

The Company has U.S. federal net operating loss carryovers (NOLs) of approximately $101,075,000 and $75,348,000 at October 31, 2015 and 2014, respectively, available to offset taxable income which expire beginning in 2023. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. In 2016, the Company plans on undertaking a detailed analysis of any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. The Company also has New Jersey State Net Operating Loss carryovers of approximately $27,496,000 and $18,078,000 as of October 31, 2015 and October 31, 2014, respectively, available to offset future taxable income through 2035.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, Management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended October 31, 2015 and 2014, the change in the valuation allowance was approximately $16,353,960 and $4,770,000.

The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as “Other Income (Expense), Net” in the statement of operations. Penalties would be recognized as a component of “General and administrative” in the statement of operations.

No interest or penalties on unpaid tax were recorded during the years ended October 31, 2015 and October 31, 2014, respectively. As of October 31, 2015 and October 31, 2014, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.

The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the year ended October 31, 2012.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
	October 31, 2015			October 31, 2014
Deferred Tax Assets

Net operating loss carryovers	$	34,366,000		$	26,685,000
Stock-based compensation		10,282,000			3,467,000
Other deferred tax assets		4,878,000			2,094,000
Total deferred tax assets	$	49,526,000		$	32,246,000
Valuation allowance		(47,466,000	)		(31,112,000	)
Deferred tax asset, net of valuation allowance	$	2,060,000		$	1,134,000

Deferred Tax Liabilities

Other deferred tax liabilities		(2,060,000	)		(1,134,000	)
Total deferred tax liabilities	$	(2,060,000	)	$	(1,134,000	)
Net deferred tax asset (liability)	$	-		$	-

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2015			October 31, 2014
US Federal statutory rate		34.0	%		34.0
State income tax, net of federal benefit		5.9			5.9
Deferred tax adjustment		(2.2	)		(13.3	)
Change in valuation allowance		(33.6	)		(25.3	)
Income tax benefit from sale of New Jersey NOL carryovers		3.3			12.5
Other permanent differences		(4.1	)		(1.3	)
Income tax (provision) benefit		3.3	%		12.5	%

Shareholders' Equity

12 Months Ended

Oct. 31, 2015

Equity [Abstract]

Shareholders' Equity

12. SHAREHOLDERS’ EQUITY:

Registered Direct Offerings

On August 26, 2015, the Company entered into a licensing agreement with Knight Therapeutics Inc. (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, to commercialize in Canada the Company’s product candidates. Under the terms of the licensing agreement, Knight will be responsible to conduct and fund all regulatory and commercial activities in Canada. The Company is eligible to receive royalty and sales milestones as defined in the agreement.

In connection with the licensing agreement, the Company sold directly to Knight 359,454 shares of the common stock at $13.91 per share. In addition, the Company sold directly to Sectoral Asset Management, a leading Canadian-based global healthcare investment advisor, 1,437,815 shares of common stock at $13.91 per share. The combined net proceeds to the Company from these direct investments was approximately $25 million. The sale of the shares closed on August 28, 2015.

On February 18, 2015, the Company priced a registered direct offering of 3,068,095 shares of its Common Stock at $7.50 per share. The transaction closed on February 19, 2015, and the Company received gross proceeds of approximately $23.0 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $22.3 million.

On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock at $4.25 per share. The transaction closed on December 22, 2014, and the Company received gross proceeds of approximately $16.7 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $15.8 million.

Public Offerings

On May 5, 2015, the Company closed on an underwritten public offering of 2,800,000 shares of Common Stock at a public offering price of $19.00 per share. On May 20, 2015, the Company closed the underwriters’ overallotment option to purchase 420,000 shares of its Common Stock at a public offering price of $19.00 per share. The Company received gross proceeds of approximately $61.2 million from the May 2015 public offerings. After deducting offering expenses, the net proceeds from the May 2015 public offerings were approximately $56.7 million.

On March 31, 2014, the Company closed its public offering of 4,692,000 shares of Common Stock, including 612,000 shares that were offered and sold by the Company pursuant to the full exercise of the underwriters’ over-allotment option, at a price to the public of $3.00 per share. Total gross proceeds from the offering were $14 million. After deducting underwriting discounts and commissions and other offering expenses paid by the Company, net proceeds were approximately $12.7 million.

Licensing Agreement – Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC).

GBP plans to conduct registration trials with axalimogene filolisbac for the treatment of advanced cervical cancer. GBP is also planning to conduct a randomized Phase 2, open-label, controlled study in HPV-associated NSCLC in patients following first-line induction chemotherapy. Pending Taiwanese FDA approval, the study is planned to initiate in 2016 and will enroll up to 124 patients. This trial will be fully funded by GBP. GBP will continue to explore the use of our lead product candidate in several other indications including head and neck, and anal cancer.

GBP will pay Advaxis event-based financial milestones, an annual development fee, and annual net sales royalty payments in the high single to double digits. In addition, as an upfront payment, GBP made an investment in Advaxis of $400,000 by purchasing from the Company 108,724 shares of its Common Stock at a price of $3.68 per share, GBP also received 100,000 warrants at an exercise price of $5.52 which expire in December 2018.

GBP will be responsible for all clinical development and commercialization costs in the GBP territory. GBP will also reimburse the Company $2.25 million toward its U.S. registrational study, where such payment will help to offset development costs. GBP is committed to establishing manufacturing capabilities for its own territory and to serving as a secondary manufacturing source for Advaxis in the future. Under the terms of the agreement, Advaxis will exclusively license the rights of axalimogene filolisbac to GBP for Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis retains exclusive rights to axalimogene filolisbac for the rest of the world.

Licensing Agreement – Aratana Therapeutics

On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue in the three months ended April 30, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement.

Advaxis (i) issued and sold 306,122 shares of Advaxis’ Common Stock to Aratana at a price of $4.90 per share, which was equal to the closing price of the Common Stock on the NASDAQ Capital Market on March 19, 2014, and (ii) issued a ten-year warrant to Aratana giving Aratana the right to purchase up to 153,061 additional shares of Advaxis’ Common Stock at an exercise price of $4.90 per share. In connection with the sale of the Common Stock and warrants, Advaxis received aggregate net proceeds of $1,500,000.

Based on the above licensing agreement, the Company expects to derive the majority of revenue from patent licensing if clinical development is successful. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

Stock Purchase Agreements

On May 15, 2014, the Company issued 45,323 shares of its Common Stock pursuant to the Securities Purchase Agreement with Yenson.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Fair Value

12 Months Ended

Oct. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2015 and October 31, 2014:

October 31, 2015	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from November 2015 through August 2017		-		-		89,211		89,211

October 31, 2014	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$	-	$	32,091	$	32,091

Common stock warrant liability:

	October 31,
	2015		2014
Beginning balance	$	32,091	$	646,734
Issuance of additional warrants due to anti-dilution provisions		8,169		4,446
Change in fair value		48,950		(619,089	)
Ending Balance	$	89,211	$	32,091

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Subsequent Events

12 Months Ended

Oct. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

14. SUBSEQUENT EVENTS

On November 3, 2015, the Company issued 1,667 shares of Common Stock to a member of management, which represents the anniversary vesting period of an inducement grant pursuant to his Employment Agreement.

On November 5, 2015, the Company granted to executives 1,090,000 options with a fair value of $11,677,538. The options vest annually in equal installments such that 100% of the options will by the third anniversary of the grant date, and the vesting of 350,000 of the options are subject to a performance condition. The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary.

On November 5, 2015, the Company granted to Directors 295,000 options with a fair value of $3,160,432. The options vest annually in equal installments such that 100% of the options will by the third anniversary of the grant date. The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary.

On November 5, 2015, the Company issued 4,687 shares of Common Stock to the Board of Directors, which represents a portion of their quarterly retainer fees.

On November 16, 2015, the Company issued 2,500 shares of Common Stock a member of management, which represents the initial vesting period of an inducement grant pursuant to his Employment Agreement.

On November 20, 2015, the Company issued 16,467 shares of Common Stock valued at $203,547 to accredited investors as payment for consulting services rendered.

On November 30, 2015, the Company issued 1,195 shares of Common Stock to its Executive Officers, pursuant to their Employment Agreements.

On December 1, 2015, the Company issued 1,657 shares of Common Stock valued at $20,000 to an accredited investor as payment for consulting services rendered.

On December 7, 2015, the Company issued 1,875 shares of Common Stock to members of management, which represents the initial vesting period of an inducement grant pursuant to their Employment Agreements.

On December 21, 2015, the Company issued 5,625 shares of Common Stock to members of management, which represents the initial vesting period of an inducement grant pursuant to their Employment Agreements.

On December 29, 2015, the Company issued 122,662 shares of Common Stock to an accredited investor, pursuant to a warrant exercise.

On December 31, 2015, the Company issued 2,044 shares of Common Stock to its Executive officers, pursuant to their Employment Agreements.

On January 4, 2016, the Company issued 11,875 shares of Common Stock to members of management, which represents the initial vesting period of an inducement grant pursuant to their Employment Agreements.

On January 7, 2016, the Company issued 5,000 of Common Stock valued at $43,150 to an accredited investor as payment for consulting services rendered.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Oct. 31, 2015

Accounting Policies [Abstract]

Estimates

Estimates

Reclassification

Reclassification

Revenue Recognition

Revenue Recognition

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Investments

Investments

Deferred Expenses

Deferred Expenses

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Net Loss per Share

Net Loss per Share

	As of October 31,
	2015		2014
Warrants		3,241,466		4,158,092
Stock Options		1,981,939		467,968
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,224,981		4,629,414

Research and Development Expenses

Research and Development Expenses

Stock Based Compensation

Stock Based Compensation

Treasury Stock

Treasury Stock

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Derivative Financial Instruments

Derivative Financial Instruments

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Income Taxes

Income Taxes

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Oct. 31, 2015

Accounting Policies [Abstract]

Schedule of Common Stock Excluded from Diluted Net Loss Per Share

The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of October 31,
	2015		2014
Warrants		3,241,466		4,158,092
Stock Options		1,981,939		467,968
Convertible Debt (using the if-converted method)		1,576		3,354
Total		5,224,981		4,629,414

Investments (Tables)

12 Months Ended

Oct. 31, 2015

Investments

Schedule of Investment Securities at Amortized

The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2015:

	October 31, 2015
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	12,628,880	$	-	$	-	$	12,628,880
Domestic Governmental Agency Loans		27,951,633		5,827		5,979		27,951,481
U.S Treasury Notes		5,013,982		700		262		5,014,420
Total short-term investment securities	$	45,594,495	$	6,527	$	6,241	$	45,594,781

Property and Equipment (Tables)

12 Months Ended

Oct. 31, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following:

	October 31,
	2015			2014
Leasehold Improvements	$	237,209		$	-
Laboratory Equipment		532,249			250,456
Furniture and Fixtures		331,500			72,554
Computer Equipment		48,745			10,717
Construction in Progress		80,538			-
Total Property and Equipment		1,230,241			333,727
Accumulated Depreciation and Amortization		(142,997	)		(256,358	)
Net Property and Equipment	$	1,087,244		$	77,369

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31,
	2015			2014
License	$	651,992		$	651,992
Patents		3,898,493			3,111,624
Total intangibles		4,550,485			3,763,616
Accumulated Amortization		(1,195,452	)		(995,671	)
Net Intangible Assets	$	3,355,033		$	2,767,945

Schedule of Amortization Expense

Estimated amortization expense for the next five years is as follows:

Year ending October 31,
2016	$	221,000
2017	$	221,000
2018	$	221,000
2019	$	221,000
2020	$	221,000

Accrued Expenses (Tables)

12 Months Ended

Oct. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The following table represents the major components of accrued expenses:

	October 31,
	2015		2014
Salaries and other compensation	$	1,698,371	$	890,069
Vendors		1,000,579		121,200
Professional Fees		272,058		208,000
Withholding taxes payable		220,933		22,527
Total Accrued Expenses	$	3,191,941	$	1,241,796

Common Stock Purchase Warrants and Warrant Liability (Tables)

12 Months Ended

Oct. 31, 2015

Common Stock Purchase Warrants And Warrant Liability

Schedule of Warrants Outstanding

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	18.75		7,902	January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	10.63		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.63-18.75		3,172	November 2015 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	2.76-5.52		122,661	December 2015 – March 2024	Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75		1,778	August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,043,477	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	3.75-5.00		28,375	October 2018 – March 2019	Representative – Advaxis Public Offering
		Grand Total		3,241,466

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		10,059	October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 – January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	7.77-21.25		112,460	December 2014 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		7,855	January 2015 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	4.90		30,154	September 2015	Consultant
Common Stock Purchase Warrant	$	2.76-5.52		277,055	December 2015 – March 2024	Stock Purchase Agreement
Common Stock Purchase Warrant	$	5.625-18.75		13,095	October 2015 – August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,306,200	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	3.75-5.00		320,775	October 2018 – March 2019	Representative – Advaxis Public Offering
		Grand Total		4,158,092

Schedule of Warrants Activity

A summary of changes in warrants for the years ended October 31, 2015 and 2014 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and Exercisable Warrants at October 31, 2013		4,265,262		$	6.71		4.22	$	22,208
Issued		412,693			4.97
Exercised		(50	)		5.00
Expired		(519,813	)		15.01
Outstanding and Exercisable Warrants at October 31, 2014		4,158,092		$	5.43		3.94	$	9,518
Issued		2,361			7.20
Exercised *		(769,349	)		5.12
Expired		(149,638	)		14.61
Outstanding and Exercisable Warrants at October 31, 2015		3,241,466		$	5.07		2.90	$	19,588,099

* Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock.

Schedule of Fair Value of Warrant Liability

In fair valuing the warrant liability, at October 31, 2015 and October 31, 2014, the Company used the following inputs in its BSM:

		10/31/2015			10/31/2014

Exercise Price	$	10.63-18.75		$	2.76-21.25
Stock Price	$	11.09		$	3.18
Expected Term		1.52-1.76 years			0.01-2.76 years
Volatility %		93.87%-95.00	%		55.41% -129.38	%
Risk Free Rate		.075	%		.01%-1.62	%

Share Based Compensation (Tables)

12 Months Ended

Oct. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Allocation of Base Salary

The table below reflects the purchases of each Executive:

	ANNUALIZED
	Annual Amount		For the Year Ended October 31, 2015
	to be Purchased		Gross Purchase				Net Purchase
Executive	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	89,064	$	88,840		8,482	$	76,451		7,556
David J. Mauro	$	16,531	$	16,491		1,591	$	12,729		1,252
Gregory T. Mayes	$	23,477	$	23,312		2,180	$	18,740		1,781
Robert G. Petit	$	25,225	$	25,220		2,443	$	19,000		1,886
Sara M. Bonstein	$	19,734	$	19,597		1,837	$	15,662		1,473

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the twelve months ended October 31, 2015 and 2014 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2013:		112,500		$	3.57
Granted		1,268,580			3.88
Vested		(547,030	)		3.91
Cancelled		(42,171	)		4.14
Balance at October 31, 2014:		791,879		$	3.81
Granted		864,192			15.14
Vested		(583,403	)		7.58
Cancelled		(3,333	)		11.76
Balance at October 31, 2015		1,069,335		$	10.89

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the twelve months ended October 31, 2015 and 2014 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2013		467,923		$	15.86		7.28	$	-
Granted		36,000			4.02		9.16
Cancelled or Expired		(35,955	)		8.57		-
Outstanding as of October 31, 2014		467,968		$	15.51		6.34	$	-
Granted		1,668,995			13.41		9.42
Exercised *		(137,667	)		12.29
Cancelled or Expired		(17,357	)		36.24
Outstanding as of October 31, 2015		1,981,939		$	13.78		8.72	$	285,330
Vested and Exercisable at October 31, 2015		711,742		$	14.15		7.46	$	270,556

* Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Summary of Outstanding and Exercisable Options

The following table summarizes information about the outstanding and exercisable options at October 31, 2015.

	Options Outstanding								Options Exercisable
			Weighted		Weighted						Weighted
			Average		Average						Average
Exercise	Number		Remaining		Exercise		Intrinsic		Number		Exercise		Intrinsic
Price Range	Outstanding		Contractual		Price		Value		Exercisable		Price		Value

$3.00 - $9.99		119,720		7.40	$	8.71	$	285,330		117,719	$	8.79	$	270,556
$10.00 - $14.99		1,621,605		9.24	$	13.41	$	-		403,409	$	13.31	$	-
$15.01 - $19.99		224,669		6.33	$	18.06	$	-		174,669	$	18.30	$	-
$20.00 - $36.00		15,945		0.45	$	29.27	$	-		15,945	$	29.27	$	-

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the twelve months ended October 31, 2015 and 2014, the Company used the following inputs in its BSM:

	Year Ended
	October 31, 2015			October 31, 2014

Expected Term		5-10 years			5 years
Expected Volatility		109.26%-154.54	%		151.38%-171.12	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.41%-2.27	%		1.39%-1.72	%

Summary of Share-based Compensation Expense

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for years ended October 31, 2015 and 2014, respectively:

	Year Ended October 31,
	2015		2014
Research and development	$	6,293,791	$	1,250,747
General and administrative		15,137,239		4,114,863
Total	$	21,431,030	$	5,365,610

Commitments and Contingencies (Tables)

12 Months Ended

Oct. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments of Operating Leases

Future minimum payments of the Company’s operating leases are as follows:

Year ended October 31,

2016	$	440,208
2017		450,541
2018		468,947
2019		488,153
2020		507,359
Thereafter		1,117,949

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2015

Income Tax Disclosure [Abstract]

Components of Income Tax Provision (Benefit)

The income tax provision (benefit) consists of the following:

	October 31, 2015			October 31, 2014
Federal
Current	$	-		$	-
Deferred		(14,513,684	)		(5,777,937	)
State and Local
Current		(1,609,349	)		(2,356,880	)
Deferred		(1,840,276	)		1,008,338
Change in valuation allowance		16,353,960			4,769,599
Income tax provision (benefit)	$	(1,609,349	)	$	(2,356,880	)

Schedule of Deferred Tax Assets (Liabilities)

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
	October 31, 2015			October 31, 2014
Deferred Tax Assets

Net operating loss carryovers	$	34,366,000		$	26,685,000
Stock-based compensation		10,282,000			3,467,000
Other deferred tax assets		4,878,000			2,094,000
Total deferred tax assets	$	49,526,000		$	32,246,000
Valuation allowance		(47,466,000	)		(31,112,000	)
Deferred tax asset, net of valuation allowance	$	2,060,000		$	1,134,000

Deferred Tax Liabilities

Other deferred tax liabilities		(2,060,000	)		(1,134,000	)
Total deferred tax liabilities	$	(2,060,000	)	$	(1,134,000	)
Net deferred tax asset (liability)	$	-		$	-

Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit

The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Years Ended
	October 31, 2015			October 31, 2014
US Federal statutory rate		34.0	%		34.0
State income tax, net of federal benefit		5.9			5.9
Deferred tax adjustment		(2.2	)		(13.3	)
Change in valuation allowance		(33.6	)		(25.3	)
Income tax benefit from sale of New Jersey NOL carryovers		3.3			12.5
Other permanent differences		(4.1	)		(1.3	)
Income tax (provision) benefit		3.3	%		12.5	%

Fair Value (Tables)

12 Months Ended

Oct. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2015 and October 31, 2014:

October 31, 2015	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $10.63- $18.75 from November 2015 through August 2017		-		-		89,211		89,211

October 31, 2014	Level 1		Level 2		Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from November 2014 through August 2017	$	-	$	-	$	32,091	$	32,091

Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation

Common stock warrant liability:

	October 31,
	2015		2014
Beginning balance	$	32,091	$	646,734
Issuance of additional warrants due to anti-dilution provisions		8,169		4,446
Change in fair value		48,950		(619,089	)
Ending Balance	$	89,211	$	32,091

Nature of Operations and Basis of Presentation (Details Narrative)						1 Months Ended	12 Months Ended
	Aug. 28, 2015 USD ($)	Aug. 25, 2015 $ / shares shares	Feb. 18, 2015 USD ($) shares	Dec. 19, 2014 USD ($) shares	May 31, 2014 USD ($)	May 31, 2015 USD ($)	Oct. 31, 2015 Patients	May 20, 2015 $ / shares shares	May 05, 2015 $ / shares shares
Number of patients \| Patients							110
Shares issued during period to direct offering		1,797,269	3,068,095	3,940,801
Proceeds from registered direct offering \| $			$ 22,300,000	$ 15,800,000
Number of shares closed under underwritten public offering									2,800,000
Shares closed under underwritten public offering, per share value \| $ / shares		$ 13.91							$ 19.00
Proceeds from public offering \| $	$ 25,000,000				$ 12,700,000	$ 56,700,000
Over-Allotment Option [Member]
Number of shares closed under underwritten public offering								420,000
Shares closed under underwritten public offering, per share value \| $ / shares								$ 19.00

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Cash and cash equivalents	$ 66,561,683	$ 17,606,860	$ 20,552,062
Concentration of credit risk	$ 63,900,000
Estimated useful lives of intangible assets	20 years
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Estimated useful lives of property and equipment	10 years

Summary of Significant Accounting Policies - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Number of common stock excluded from diluted net loss per share	5,224,981	4,629,414
Warrants [Member]
Number of common stock excluded from diluted net loss per share	3,241,466	4,158,092
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	1,981,939	467,968
Convertible Debt [Member]
Number of common stock excluded from diluted net loss per share	1,576	3,354

Investments - Schedule of Investment Securities at Amortized (Details)	12 Months Ended
	Oct. 31, 2015 USD ($)
Amortized cost, as adjusted	$ 45,594,495
Gross unrealized holding gains	6,527
Gross unrealized holding losses	6,241
Estimated fair value	45,594,781
Certificates of Deposit [Member]
Amortized cost, as adjusted	12,628,880
Gross unrealized holding gains
Gross unrealized holding losses
Estimated fair value	12,628,880
Domestic Governmental Agency Loans [Member]
Amortized cost, as adjusted	27,951,633
Gross unrealized holding gains	5,827
Gross unrealized holding losses	5,979
Estimated fair value	27,951,481
U.S Treasury Notes [Member]
Amortized cost, as adjusted	5,013,982
Gross unrealized holding gains	700
Gross unrealized holding losses	262
Estimated fair value	$ 5,014,420

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 59,033	$ 27,611

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Property, Plant and Equipment [Abstract]
Leasehold Improvements	$ 237,209
Laboratory Equipment	532,249	250,456
Furniture and Fixtures	331,500	72,554
Computer Equipment	48,745	10,717
Construction in Progress	80,538
Total Property and Equipment	1,230,241	333,727
Accumulated Depreciation and Amortization	(142,997)	(256,358)
Net Property and Equipment	$ 1,087,244	$ 77,369

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	Expirations of the existing patents range from 2015 to 2030.
Patent net book value	$ 28,480	$ 0
Amortization expense of licensed technology and capitalized patent costs	$ 206,357	$ 175,686

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 651,992	$ 651,992
Patents	3,898,493	3,111,624
Total intangibles	4,550,485	3,763,616
Accumulated Amortization	(1,195,452)	(995,671)
Net Intangible Assets	$ 3,355,033	$ 2,767,945

Intangible Assets - Schedule of Amortization Expense (Details)	Oct. 31, 2015 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 221,000
2017	221,000
2018	221,000
2019	221,000
2020	$ 221,000

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Payables and Accruals [Abstract]
Salaries and other compensation	$ 1,698,371	$ 890,069
Vendors	1,000,579	121,200
Professional Fees	272,058	208,000
Withholding taxes payable	220,933	22,527
Total Accrued Expenses	$ 3,191,941	$ 1,241,796

Convertible Notes and Fair Value of Embedded Derivative (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2015	Oct. 31, 2015	Oct. 31, 2014
Debt Disclosure [Abstract]
Short-term convertible notes and fair value of embedded derivative		$ 29,549	$ 62,882
Conversion price of convertible promissory notes	$ 1.61
Value of convertible promissory notes	$ 33,333
Number of shares issued upon conversion	4,104
Debt conversion expense		6,599
Embedded Derivative Liability		$ 0	$ 0

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Warrants outstanding	3,241,466	4,158,092	4,265,262
Fair value of warrant liability	$ 89,211	$ 32,091
Gain (Loss) on change in fair value of warrant liability	$ (48,950)	$ 619,089
Warrants with anti dilution provision	62,430	179,666
Warrants with out anti dilution provision expire unexercise	87,208	340,147
Anti-dilution provisions warrants exercise price	$ 25.00	$ 7.71
Anti-dilution provisions additional warrants issuable	2,400
Accredited Investor [Member]
Exercise price per share	$ 5.12	$ 5.00
Exercise of warrants	769,349	50
Proceeds from issuance of warrants	$ 2,342,449	$ 250
Equity Warrants [Member]
Warrants outstanding	3,240,000	4,160,000
Liability Warrant [Member]
Warrants outstanding	3,240,000	4,160,000
Number of warrants	18,000	123,000
Embedded derivative liability outstanding		4,200,000
Weighted average anti dilutive warrants		60,000
Minimum [Member]
Exercise price per share	$ 10.63	$ 2.76
Minimum [Member] \| Warrants With Anti Dilution Provisions [Member]
Anti-dilution provisions warrants exercise price	$ 7.20
Probability of exercise of additional warrants at exercise price one	40.00%
Probability of exercise of additional warrants at exercise price two	50.00%
Maximum [Member]
Exercise price per share	$ 18.75	21.25
Maximum [Member] \| Warrants With Anti Dilution Provisions [Member]
Anti-dilution provisions warrants exercise price	$ 6.00
Probability of exercise of additional warrants at exercise price one	50.00%
Probability of exercise of additional warrants at exercise price two	60.00%
Warrants [Member] \| Minimum [Member]
Exercise price per share	$ 2.76	2.76
Warrants [Member] \| Maximum [Member]
Exercise price per share	$ 18.75	$ 21.25
Common Stock [Member]
Warrants outstanding	3,241,466	4,158,092

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Outstanding (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Class of warrant outstanding, Amount	$ 3,241,466	$ 4,158,092
Common Stock Purchase Warrant [Member] \| May 2011 Convertible Debt Financing [Member]
Exercise Price		$ 18.75
Class of warrant outstanding, Amount		$ 28,632
Expiration Date		May 2015
Common Stock Purchase Warrant [Member] \| Oct 2011 Convertible Debt Financings [Member]
Exercise Price		$ 18.75
Class of warrant outstanding, Amount		$ 10,059
Expiration Date		October 2015
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member]
Exercise Price		$ 18.75
Class of warrant outstanding, Amount		$ 17,706
Common Stock Purchase Warrant [Member] \| May 2012 Convertible Debt Financing [Member]
Exercise Price		$ 18.75
Class of warrant outstanding, Amount		$ 13,333
Expiration Date		May 2017
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member]
Exercise Price, minimum		$ 7.77
Exercise Price, maximum		$ 21.25
Class of warrant outstanding, Amount		$ 112,460
Common Stock Purchase Warrant [Member] \| Vendor & Other [Member]
Exercise Price		$ 18.75
Class of warrant outstanding, Amount		$ 376
Expiration Date		N/A
Common Stock Purchase Warrant [Member] \| Placement Agent - Convertible Debt Financing [Member]
Exercise Price, minimum		$ 10.625
Exercise Price, maximum		$ 18.75
Class of warrant outstanding, Amount		$ 7,855
Common Stock Purchase Warrant [Member] \| Former Officer [Member]
Exercise Price		$ 5.00
Class of warrant outstanding, Amount		$ 20,392
Expiration Date		October 2018
Common Stock Purchase Warrant [Member] \| Consultant [Member]
Exercise Price		$ 4.90
Class of warrant outstanding, Amount		$ 30,154
Expiration Date		September 2015
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member]
Exercise Price, minimum		$ 2.76
Exercise Price, maximum		$ 5.52
Class of warrant outstanding, Amount		$ 277,055
Common Stock Purchase Warrant [Member] \| August - September 2012 Convertible Promissory Notes [Member]
Exercise Price, minimum		$ 5.625
Exercise Price, maximum		$ 18.75
Class of warrant outstanding, Amount		$ 13,095
Common Stock Purchase Warrant [Member] \| Advaxis Public Offering [Member]
Exercise Price		$ 5.00
Class of warrant outstanding, Amount		$ 3,306,200
Expiration Date		October 2018
Common Stock Purchase Warrant [Member] \| Representative Advaxis Public Offering [Member]
Exercise Price, minimum		$ 3.75
Exercise Price, maximum		$ 5.00
Class of warrant outstanding, Amount		$ 320,775
Common Stock Purchase Warrant [Member] \| Minimum [Member] \| December 2011 Convertible Debt Financing [Member]
Expiration Date		May 2015
Common Stock Purchase Warrant [Member] \| Minimum [Member] \| Bridge Notes [Member]
Expiration Date		December 2014
Common Stock Purchase Warrant [Member] \| Minimum [Member] \| Placement Agent - Convertible Debt Financing [Member]
Expiration Date		January 2015
Common Stock Purchase Warrant [Member] \| Minimum [Member] \| Stock Purchase Agreement [Member]
Expiration Date		December 2015
Common Stock Purchase Warrant [Member] \| Minimum [Member] \| August - September 2012 Convertible Promissory Notes [Member]
Expiration Date		October 2015
Common Stock Purchase Warrant [Member] \| Maximum [Member] \| December 2011 Convertible Debt Financing [Member]
Expiration Date		January 2016
Common Stock Purchase Warrant [Member] \| Maximum [Member] \| Bridge Notes [Member]
Expiration Date		April 2015
Common Stock Purchase Warrant [Member] \| Maximum [Member] \| Placement Agent - Convertible Debt Financing [Member]
Expiration Date		May 2017
Common Stock Purchase Warrant [Member] \| Maximum [Member] \| Stock Purchase Agreement [Member]
Expiration Date		March 2024
Common Stock Purchase Warrant [Member] \| Maximum [Member] \| August - September 2012 Convertible Promissory Notes [Member]
Expiration Date		August 2017
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member]
Exercise Price	$ 18.75
Class of warrant outstanding, Amount	$ 7,902
Expiration Date	January 2016
Common Stock Purchase Warrant [Member] \| May 2012 Convertible Debt Financing [Member]
Exercise Price	$ 10.63
Class of warrant outstanding, Amount	$ 13,333
Expiration Date	May 2017
Common Stock Purchase Warrant [Member] \| Vendor & Other [Member]
Exercise Price	$ 18.75
Class of warrant outstanding, Amount	$ 376
Expiration Date	N/A
Common Stock Purchase Warrant [Member] \| Placement Agent - Convertible Debt Financing [Member]
Exercise Price, minimum	$ 10.63
Exercise Price, maximum	$ 18.75
Class of warrant outstanding, Amount	$ 3,172
Common Stock Purchase Warrant [Member] \| Placement Agent - Convertible Debt Financing [Member] \| Minimum [Member]
Expiration Date	November 2015
Common Stock Purchase Warrant [Member] \| Placement Agent - Convertible Debt Financing [Member] \| Maximum [Member]
Expiration Date	May 2017
Common Stock Purchase Warrant [Member] \| Former Officer [Member]
Exercise Price	$ 5.00
Class of warrant outstanding, Amount	$ 20,392
Expiration Date	October 2018
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member]
Exercise Price, minimum	$ 2.76
Exercise Price, maximum	$ 5.52
Class of warrant outstanding, Amount	$ 122,661
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member] \| Minimum [Member]
Expiration Date	December 2015
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member] \| Maximum [Member]
Expiration Date	March 2024
Common Stock Purchase Warrant [Member] \| August - September 2012 Convertible Promissory Notes [Member]
Exercise Price	$ 18.75
Class of warrant outstanding, Amount	$ 1,778
Expiration Date	August 2017
Common Stock Purchase Warrant [Member] \| Advaxis Public Offering [Member]
Exercise Price	$ 5.00
Class of warrant outstanding, Amount	$ 3,043,477
Expiration Date	October 2018
Common Stock Purchase Warrant [Member] \| Representative Advaxis Public Offering [Member]
Exercise Price, minimum	$ 3.75
Exercise Price, maximum	$ 5.00
Class of warrant outstanding, Amount	$ 28,375
Common Stock Purchase Warrant [Member] \| Representative Advaxis Public Offering [Member] \| Minimum [Member]
Expiration Date	October 2018
Common Stock Purchase Warrant [Member] \| Representative Advaxis Public Offering [Member] \| Maximum [Member]
Expiration Date	March 2019
Common Stock Warrant Liability [Member] \| Minimum [Member] \| Representative Advaxis Public Offering [Member]
Expiration Date		October 2018
Common Stock Warrant Liability [Member] \| Maximum [Member] \| Representative Advaxis Public Offering [Member]
Expiration Date		March 2019

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) - USD ($)

12 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Number of Warrants, Outstanding, Beginning balance

4,158,092

4,265,262

Number of Warrants, Issued

2,361

412,693

Number of Warrants, Exercised

(769,349)

^[1]

(50)

Number of Warrants, Expired

(149,638)

(519,813)

Number of Warrants, Outstanding, Ending balance

3,241,466

4,158,092

Weighted-Average Exercise Price, Outstanding, Beginning

$ 5.43

$ 6.71

Weighted-Average Exercise Price, Issued

7.20

4.97

Weighted-Average Exercise Price, Exercised

5.12

^[1]

5.00

Weighted-Average Exercise Price, Expired

14.61

15.01

Weighted-Average Exercise Price, Outstanding, Ending

$ 5.07

$ 5.43

Weighted Average Remaining Contractual Life In Years, Beginning

3 years 11 months 9 days

4 years 2 months 19 days

Weighted Average Remaining Contractual Life In Years, Ending

2 years 10 months 24 days

3 years 11 months 9 days

Aggregate Intrinsic Value, Beginning

$ 9,518

$ 22,208

Aggregate Intrinsic Value, Ending

$ 19,588,099

$ 9,518

[1]	Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock.

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2015 shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Cashless exercise of warrants	300,376
Issuance of common stock	222,295

Common Stock Purchase Warrants and Warrant Liability - Schedule of Fair Value of Warrant Liability (Details) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Stock Price	$ 11.09	$ 3.18
Risk Free Rate	0.075%
Minimum [Member]
Exercise Price	$ 10.63	$ 2.76
Expected term:	1 year 6 months 7 days	4 days
Volatility %	93.87%	55.41%
Risk Free Rate		0.01%
Maximum [Member]
Exercise Price	$ 18.75	$ 21.25
Expected term:	1 year 9 months 4 days	2 years 9 months 4 days
Volatility %	95.00%	129.38%
Risk Free Rate		1.62%

Share Based Compensation (Details Narrative) - USD ($)				1 Months Ended		12 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	May 05, 2015	Jul. 09, 2014	May 31, 2014	Mar. 31, 2014	Oct. 31, 2013	Oct. 31, 2015	Oct. 31, 2014	Dec. 30, 2011	Sep. 27, 2011
Common stock issued during period	2,800,000		4,692,000
Stock compensation expense						$ 206,192	$ 128,271
Share-based compensation, common stock, shares						19,145	40,320
Share-based compensation, shares on net basis after employee payroll taxes						16,090	31,026
Issuance of common stock			612,000
Unrecognized compensation cost related to nonvested stock option awards						$ 10,053,000
Recognized over a remaining average vesting period						1 year 3 months 4 days
Options Outstanding Intrinsic Value						$ 285,330
Expected dividend yield percentage						0.00%
Compensation cost related to outstanding stock options						$ 21,431,030	$ 5,365,610
Number of options, granted						1,668,995	36,000
Stock Options [Member]
Unrecognized compensation cost related to nonvested stock option awards						$ 19,718,000
Recognized over a remaining average vesting period						1 year 4 months 6 days
Options Outstanding Intrinsic Value						$ 271,000
Compensation cost related to outstanding stock options						$ 9,521,000	$ 920,000
Number of options, granted						1,668,995	36,000
Fair value of option granted						$ 29,014,000	$ 145,000
Number of shares exercised						137,667
Cash proceeds from stock option exercised						$ 58,400
Director [Member]
Stock compensation expense						$ 1,223,118	$ 614,750
Share-based compensation, common stock, shares						267,186	146,899
Share-based compensation, shares on net basis after employee payroll taxes						253,754
Stock Bonus Award [Member]
Share-based compensation, common stock, shares						31,845
Share-based compensation, shares on net basis after employee payroll taxes						21,389
Performance bonus						$ 129,000
Restricted Stock Units (RSUs) [Member]
Fair value of RSU						7,771,000	$ 1,944,000
Options Outstanding Intrinsic Value						$ 217,908
Number of options, granted						864,192	1,268,580
2011 Employee Stock Purchase Plan [Member]
Shares available for issuance						22,827		40,000
Stock compensation expense						$ 28,791	$ 6,251
Share-based compensation, shares on net basis after employee payroll taxes						7,063	2,110
Discount on market price of common stock									15.00%
2013 Base Salary Stock [Member]
Issuance of common stock						34,752
Number of stock shares issued during period amount						$ 186,555
Issuance of common stock net basis after taxes						21,489
2014 Cash Bonus Equity [Member]
Issuance of common stock						62,064
Number of stock shares issued during period amount						$ 214,359
Issuance of common stock net basis after taxes						57,990
2014 Voluntary Request To Purchase Of Equity [Member]
Issuance of common stock						15,950
Number of stock shares issued during period amount						$ 68,750
Common Stock [Member]
Common stock issued during period						3,220,000	4,692,000
Share-based compensation, common stock, shares						789,438	501,651
Issuance of common stock				3,333	13,500
Number of stock shares issued during period amount				$ 10,000	$ 54,000
Promissory Note One [Member]
Issuance of common stock						21,091
Number of stock shares issued during period amount						$ 66,500
Daniel J. O' Connor [Member]
Issuance of common stock						146,616
Number of stock shares issued during period amount						$ 588,294
Executive Officer [Member]
Share-based compensation, shares on net basis after employee payroll taxes						98,603
Fair value of equity purchases value						$ 418,000
Number of shares for equity purchases						125,411
Sara M. Bonstein [Member] \| Stock Bonus Award [Member]
Stock compensation expense						$ 5,226,302	$ 1,836,143
Share-based compensation, common stock, shares						487,591	489,287
Share-based compensation, shares on net basis after employee payroll taxes						406,691	280,848
Non Executive Employees [Member] \| Stock Bonus Award [Member]
Share-based compensation, shares on net basis after employee payroll taxes						14,300
Fair value of equity purchases value						$ 67,671
Number of shares for equity purchases						20,322
Consultants [Member]
Stock issued during period for services						378,538	405,603
Stock issued during period value for services						$ 4,707,440	$ 1,551,591
Liability pursuant to consulting agreements						$ 55,000
2015 Plan [Member]
Common stock issued during period						3,600,000
Additional common stock issued during period						650,000
Shares available for issuance						2,134,468
2011 Omnibus Incentive Plan [Member] \| Minimum [Member]
Common stock issued during period		520,000
2011 Omnibus Incentive Plan [Member] \| Maximum [Member]
Common stock issued during period		2,120,000
Certificate of Incorporation [Member] \| Minimum [Member]
Common stock issued during period		25,000,000
Certificate of Incorporation [Member] \| Maximum [Member]
Common stock issued during period		45,000,000

Share Based Compensation - Schedule of Allocation of Base Salary (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Annual Amount to be Purchased	$ 21,431,030	$ 5,365,610
Cumulative Net Purchase	119,733,876	$ 14,580,808
Daniel J. O' Connor [Member]
Annual Amount to be Purchased	89,064
Cumulative Gross Purchase	$ 88,840
Cumulative shares Gross Purchase	8,482
Cumulative Net Purchase	$ 76,451
Cumulative shares Net Purchase	7,556
David J. Mauro [Member]
Annual Amount to be Purchased	$ 16,531
Cumulative Gross Purchase	$ 16,491
Cumulative shares Gross Purchase	1,591
Cumulative Net Purchase	$ 12,729
Cumulative shares Net Purchase	1,252
Gregory T. Mayes [Member]
Annual Amount to be Purchased	$ 23,477
Cumulative Gross Purchase	$ 23,312
Cumulative shares Gross Purchase	2,180
Cumulative Net Purchase	$ 18,740
Cumulative shares Net Purchase	1,781
Robert G. Petit [Member]
Annual Amount to be Purchased	$ 25,225
Cumulative Gross Purchase	$ 25,220
Cumulative shares Gross Purchase	2,443
Cumulative Net Purchase	$ 19,000
Cumulative shares Net Purchase	1,886
Sara M. Bonstein [Member]
Annual Amount to be Purchased	$ 19,734
Cumulative Gross Purchase	$ 19,597
Cumulative shares Gross Purchase	1,837
Cumulative Net Purchase	$ 15,662
Cumulative shares Net Purchase	1,473

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares

12 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Beginning balance

467,968

467,923

Number of RSUs Granted

1,668,995

36,000

Number of RSUs Vested

(137,667)

^[1]

Number of RSUs Cancelled

17,357

35,955

Ending Balance

1,981,939

467,968

Weighted-Average Exercise Price, Outstanding, Beginning

$ 15.51

$ 15.86

Weighted-Average Exercise Price, Granted

13.41

4.02

Weighted-Average Exercise Price, Vested

12.29

^[1]

Weighted-Average Exercise Price, Cancelled

36.24

8.57

Weighted-Average Exercise Price, Outstanding, Ending

$ 13.78

$ 15.51

Restricted Stock Units (RSUs) [Member]

Beginning balance

791,879

112,500

Number of RSUs Granted

864,192

1,268,580

Number of RSUs Vested

(583,403)

(547,030)

Number of RSUs Cancelled

(3,333)

(42,171)

Ending Balance

1,069,335

791,879

Weighted-Average Exercise Price, Outstanding, Beginning

$ 3.81

$ 3.57

Weighted-Average Exercise Price, Granted

15.14

3.88

Weighted-Average Exercise Price, Vested

7.58

3.91

Weighted-Average Exercise Price, Cancelled

11.76

4.14

Weighted-Average Exercise Price, Outstanding, Ending

$ 10.89

$ 3.81

[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - USD ($)

12 Months Ended

Oct. 31, 2015

Oct. 31, 2014

Oct. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Beginning balance

467,968

467,923

Number of Options, Granted

1,668,995

36,000

Number of Options, Cancelled or Expired

(17,357)

(35,955)

Number of Options, Exercised

(137,667)

^[1]

Ending Balance

1,981,939

467,968

467,923

Number of Options, Vested and Exercisable

711,742

Weighted-Average Exercise Price, Outstanding, Beginning

$ 15.51

$ 15.86

Weighted-Average Exercise Price, Granted

13.41

4.02

Weighted-Average Exercise Price, Cancelled or Expired

36.24

8.57

Weighted-Average Exercise Price, Exercised

12.29

^[1]

Weighted-Average Exercise Price, Outstanding, Ending

13.78

15.51

$ 15.86

Weighted-Average Exercise Price, Vested and Exercisable

$ 14.15

Weighted Average Remaining Contractual Life In Years

8 years 8 months 19 days

6 years 4 months 2 days

7 years 3 months 11 days

Weighted Average Remaining Contractual Life In Years, Granted

9 years 5 months 1 day

9 years 1 month 28 days

Weighted Average Remaining Contractual Life In Years, Vested and Exercisable

7 years 5 months 16 days

Aggregate Intrinsic Value, Beginning

Aggregate Intrinsic Value, Ending

285,330

Aggregate Intrinsic Value, Vested and Exercisable

$ 270,556

[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2015 shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Cashless exercise of stock options	117,667
Stock option resulted number of issuance of common stock	45,167

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014	Oct. 31, 2013
Options Outstanding Weighted Average Exercise Price	$ 13.78	$ 15.51	$ 15.86
Number Outstanding	1,981,939	467,968	467,923
Weighted Average Remaining Contractual	8 years 8 months 19 days	6 years 4 months 2 days	7 years 3 months 11 days
Options Outstanding Intrinsic Value	$ 285,330
Number Exercisable	711,742
Options Exercisable Weighted Average Exercise Price	$ 14.15
Exercise Price Range $3.00 - $9.99 [Member]
Options Outstanding Weighted Average Exercise Price	$ 8.71
Number Outstanding	119,720
Weighted Average Remaining Contractual	7 years 4 months 24 days
Options Outstanding Intrinsic Value	$ 285,330
Number Exercisable	117,719
Options Exercisable Weighted Average Exercise Price	$ 8.79
Options Exercisable Intrinsic Value	$ 270,556
Exercise Price Range $3.00 - $9.99 [Member] \| Minimum [Member]
Options Outstanding Weighted Average Exercise Price	$ 3.00
Exercise Price Range $3.00 - $9.99 [Member] \| Maximum [Member]
Options Outstanding Weighted Average Exercise Price	9.99
Exercise Price Range $10.00 - $14.99 [Member]
Options Outstanding Weighted Average Exercise Price	$ 13.41
Number Outstanding	1,621,605
Weighted Average Remaining Contractual	9 years 2 months 27 days
Options Outstanding Intrinsic Value
Number Exercisable	403,409
Options Exercisable Weighted Average Exercise Price	$ 13.31
Options Exercisable Intrinsic Value
Exercise Price Range $10.00 - $14.99 [Member] \| Minimum [Member]
Options Outstanding Weighted Average Exercise Price	$ 10.00
Exercise Price Range $10.00 - $14.99 [Member] \| Maximum [Member]
Options Outstanding Weighted Average Exercise Price	14.99
Exercise Price Range $15.01 - $19.99 [Member]
Options Outstanding Weighted Average Exercise Price	$ 18.06
Number Outstanding	224,669
Weighted Average Remaining Contractual	6 years 3 months 29 days
Options Outstanding Intrinsic Value
Number Exercisable	174,669
Options Exercisable Weighted Average Exercise Price	$ 18.30
Options Exercisable Intrinsic Value
Exercise Price Range $15.01 - $19.99 [Member] \| Minimum [Member]
Options Outstanding Weighted Average Exercise Price	$ 15.01
Exercise Price Range $15.01 - $19.99 [Member] \| Maximum [Member]
Options Outstanding Weighted Average Exercise Price	19.99
Exercise Price Range $20.00 - $36.00 [Member]
Options Outstanding Weighted Average Exercise Price	$ 29.27
Number Outstanding	15,945
Weighted Average Remaining Contractual	5 months 12 days
Options Outstanding Intrinsic Value
Number Exercisable	15,945
Options Exercisable Weighted Average Exercise Price	$ 29.27
Options Exercisable Intrinsic Value
Exercise Price Range $20.00 - $36.00 [Member] \| Minimum [Member]
Options Outstanding Weighted Average Exercise Price	$ 20.00
Exercise Price Range $20.00 - $36.00 [Member] \| Maximum [Member]
Options Outstanding Weighted Average Exercise Price	$ 36.00

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Expected Term		5 years
Expected Volatility, Minimum	109.26%	151.38%
Expected Volatility, Maximum	154.54%	171.12%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	1.41%	1.39%
Risk Free Interest Rate, Maximum	2.27%	1.72%
Minimum [Member]
Expected Term	5 years
Maximum [Member]
Expected Term	10 years

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Share-based compensation expense	$ 21,431,030	$ 5,365,610
Research and Development Expenses [Member]
Share-based compensation expense	6,293,791	1,250,747
General and Administrative Expenses [Member]
Share-based compensation expense	$ 15,137,239	$ 4,114,863

Commitments and Contingencies (Details Narrative)				1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Narrative)	Aug. 21, 2015 $ / shares shares	Oct. 01, 2014 USD ($)	Apr. 01, 2011	May 31, 2015 USD ($) ft²	Oct. 31, 2015 USD ($)	Oct. 31, 2014 USD ($)	Oct. 31, 2013 USD ($)	Oct. 31, 2012 USD ($)
Research and development expenses					$ 24,220,610	$ 8,687,168
Area of square foot of space \| ft²				20,000
Lease term				7 years
Lease expire				Nov. 30, 2022
Security deposit				$ 82,426
Base annual rent				$ 442,000
Operating leases annual rent, description				The lease requires base annual rent of approximately $442,000 with annual increases in increments between 2% and 4% throughout the remainder of the lease. Rent expense will be recognized on a straight line basis over the term of the lease. The lease contains two options to renew for five years each.
Leases renewal term				5 years
Rent expense					150,000	330,000
Net cash amount received from sale of net operating losses and research and development tax credits						1,609,349	$ 1,731,317	$ 1,731,317
Sublease Agreement [Member]
Agreement expiration date			Nov. 29, 2015
Incyte Agreement [Member]
Research and development expenses					124,100
Merck Agreement [Member]
Research and development expenses					1,723,000	72,000
MedImmune Agreement [Member]
Research and development expenses					$ 1,888,000	$ 50,000
KCM [Member]
Number of shares complaint alleges of common stock \| shares	1,666,666.67
Common stock price per share \| $ / shares	$ 3.00
Numoda Corporation [Member]
Seeking declaratory judgment amount		$ 68,884

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Oct. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2016	$ 440,208
2017	450,541
2018	468,947
2019	488,153
2020	507,359
Thereafter	$ 1,117,949

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
U.S. federal net operating loss carryovers (NOLs)	$ 101,075,000	$ 75,348,000
Operating loss expiration year	2023
Minimum percentage of ownership change as determined under regulations	50.00%
New Jersey State Net Operating Loss carryovers	$ 27,496,000	18,078,000
Change in valuation allowance	16,353,960	4,770,000
Interest or penalties on unpaid tax	0	0
Liability for unrecognized tax benefits	$ 0	$ 0

Income Taxes - Components of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
Current Federal
Deferred Federal	(14,513,684)	(5,777,937)
Current State and Local	(1,609,349)	(2,356,880)
Deferred State and Local	(1,840,276)	1,008,338
Change in valuation allowance	16,353,960	4,769,599
Income tax provision (benefit)	$ (1,609,349)	$ (2,356,880)

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 34,366,000	$ 26,685,000
Stock-based compensation	10,282,000	3,467,000
Other deferred tax assets	4,878,000	2,094,000
Total deferred tax assets	49,526,000	32,246,000
Valuation allowance	(47,466,000)	(31,112,000)
Deferred tax asset, net of valuation allowance	2,060,000	1,134,000
Other deferred tax liabilities	(2,060,000)	(1,134,000)
Total deferred tax liabilities	(2,060,000)	(1,134,000)
Net deferred tax asset (liability)

Income Taxes - Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Income Tax Disclosure [Abstract]
US Federal statutory rate	34.00%	34.00%
State income tax, net of federal benefit	5.90%	5.90%
Deferred tax adjustment	(2.20%)	(13.30%)
Change in valuation allowance	(33.60%)	(25.30%)
Income tax benefit from sale of New Jersey NOL carryovers	3.30%	12.50%
Other permanent differences	(4.10%)	(1.30%)
Income tax (provision) benefit	3.30%	12.50%

Shareholders' Equity (Details Narrative) - USD ($)											1 Months Ended	3 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Aug. 28, 2015	Aug. 26, 2015	May 20, 2015	May 05, 2015	Feb. 18, 2015	Dec. 19, 2014	May 31, 2014	May 15, 2014	Mar. 19, 2014	Dec. 09, 2013	May 31, 2015	Apr. 30, 2014
Number of common stock shares sold							612,000
Common stock price per share			$ 19.00	$ 19.00	$ 7.50	$ 4.25	$ 3.00
Proceeds from direct investments		$ 25,000,000
Number of shares issued during period for registered direct offering					3,068,095	3,940,801
Proceeds from received from offering					$ 23,000,000	$ 16,700,000
Proceeds from registered direct offering, net of offering expenses					$ 22,300,000	$ 15,800,000
Number of common stock shares issued for public offering				2,800,000			4,692,000
Number of overallotment option to purchase of common stock shares			420,000
Gross proceeds from public offering							$ 14,000,000				$ 61,200,000
Proceeds from public offering	$ 25,000,000						$ 12,700,000				$ 56,700,000
Knight TherapeuticsInc [Member]
Number of common stock shares sold		1,437,815
Common stock price per share		$ 13.91
Global BioPharma, Inc [Member]
Common stock price per share										$ 3.68
Number of common stock shares issued for public offering										108,724
Investment										$ 400,000
Number of warrants issued during period										100,000
Warrants exercise price per share										$ 5.52
Warrants expiration date										2018-12
Reimburse amount										$ 2,250,000
Aratana Therapeutics [Member]
Common stock price per share									$ 4.90
Number of common stock shares issued for public offering									306,122
Warrants exercise price per share									$ 4.90
Warrant term									10 years
Number of warrants issued to purchase of common stock shares									153,061
Proceeds from issuance of warrants									$ 1,500,000
Licensing Agreement [Member] \| Knight Therapeutics Inc [Member]
Number of common stock shares sold		359,454
Common stock price per share		$ 13.91
Aratana Agreement [Member]
Licensing revenue									1,000,000			$ 1,000,000
Payment of license									36,500,000
Payment of cumulative sales of milestones									$ 15,000,000
Stock Purchase Agreements [Member] \| Yenson [Member]
Number of common stock shares issued for public offering								45,323

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Oct. 31, 2015	Oct. 31, 2014
Common stock warrant liability, warrants exercisable	$ 89,211	$ 32,091
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 89,211	$ 32,091

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Warrants exercisable period	November 2015 through August 2017	November 2014 through August 2017
Minimum [Member]
Exercise price per share	$ 10.63	$ 2.76
Maximum [Member]
Exercise price per share	$ 18.75	$ 21.25

Fair Value - Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)	12 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Fair Value Disclosures [Abstract]
Beginning balance	$ 32,091	$ 646,734
Issuance of additional warrants due to anti-dilution provisions	8,169	4,446
Change in fair value	48,950	(619,089)
Ending Balance	$ 89,211	$ 32,091

Subsequent Events (Details Narrative) - USD ($)	Jan. 07, 2016	Jan. 04, 2016	Dec. 31, 2015	Dec. 29, 2015	Dec. 21, 2015	Dec. 07, 2015	Dec. 01, 2015	Nov. 30, 2015	Nov. 20, 2015	Nov. 16, 2015	Nov. 05, 2015	Nov. 03, 2015	May 05, 2015	May 31, 2014
Common stock issued during period													2,800,000	4,692,000
Subsequent Event [Member] \| Executives [Member]
Number of stock options ganted											1,090,000
Fair value of stock option											$ 11,677,538
Percentage of options vested during period											100.00%
Stock option vesting shares											350,000
Stock options vest term description											The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary.
Subsequent Event [Member] \| Directors [Member]
Number of stock options ganted											295,000
Fair value of stock option											$ 3,160,432
Percentage of options vested during period											100.00%
Stock options vest term description											The stock options vest one-third after the one year anniversary, one-third after the two year anniversary and one-third after the three year anniversary.
Subsequent Event [Member] \| Board of Directors [Member]
Common stock issued during period											4,687
Subsequent Event [Member] \| Accredited Investor [Member]
Number of common stock shares issued for services	5,000			122,662			1,657		16,467
Number of common stock issued value for services	$ 43,150						$ 20,000		$ 203,547
Subsequent Event [Member] \| Employment Agreement [Member]
Common stock issued during period		11,875	2,044		5,625	1,875				2,500		1,667
Subsequent Event [Member] \| Employment Agreement [Member] \| Executive Officers [Member]
Common stock issued during period								1,195